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ABSTRACT	
Hematopoietic	 progenitors	 in	 the	 bone	 marrow	 differentiate	 into	 several	 immune	 cells,	
including	 mast	 cells.	 Mast	 cell	 progenitors	 leave	 the	 bone	 marrow,	 circulate	 through	 the	
blood,	and	home	to	the	periphery	where	they	mature.	This	thesis	aims	to	gain	more	insights	
into	the	development	of	mast	cells	in	health	and	in	the	mast	cell	disease	systemic	mastocytosis	
(SM).	 This	 disease	 is	 characterized	by	 infiltrates	 of	 neoplastic	mast	 cells	 in	 different	 tissues	
and	the	presence	of	the	D"#$V	mutation	in	the	KIT	gene.	In	this	thesis	we	study	mast	cells	and	
their	 progenitors	 in	 peripheral	 blood	 and	 bone	marrow	 by	 using	 multi-color	 fluorescence-
activated	 cell	 sorting	 that	 enables	 characterization	 and	 isolation	 of	 cells	 of	 interest.	 Sorted	
cells	were	analyzed	using	culture	experiments,	cytochemical	stainings	techniques,	and	genetic	
mutation	profiling.	
In	study	 I	we	analyzed	peripheral	blood	samples	 from	SM	patients	 for	 the	presence	of	mast	
cells,	 which	 are	 absent	 in	 blood	 of	 healthy	 subjects.	 In	 this	 study	 we	 demonstrated	 the	
presence	of	circulating	mature	mast	 cells	 in	 the	peripheral	blood	of	patients	with	advanced	
forms	of	SM.	
In	 study	 II	 we	 assessed	 the	 role	 of	 SCF	 and	 KIT	 signaling	 in	 mast	 cell	 development	 and	
differentiation.	 Treatment	 with	 the	 tyrosine	 kinase	 inhibitor	 imatinib,	 which	 prevents	 KIT	
signaling,	did	not	reduce	the	percentage	of	mast	cell	progenitors	in	vivo.	Using	in	vitro	culture	
experiments,	we	 further	 showed	 that	 mast	 cell	 progenitors	 from	 peripheral	 blood	 survive,	
differentiate,	and	partially	mature	without	SCF	and	KIT	signaling.		
In	study	III	we	aimed	to	investigate	the	KIT	D"#$V	distribution	throughout	the	hematopoietic	
landscape.	We	developed	 an	 assay	 that	 allows	 the	 detection	 of	 the	KIT	D"#$V	mutation	 in	
single	cells	sorted	from	the	bone	marrow	of	SM	patient.	We	detected	the	KIT	D"#$V	mutation	
throughout	the	hematopoietic	 landscape,	from	stem	cells	to	the	mast	cells	 lineage.	However	
flow	 cytometry	 analysis	 showed	 that	 the	 frequencies	 of	 different	 hematopoietic	 stem	 and	
progenitors	were	comparable	in	SM	patients	and	controls.	In	addition,	we	demonstrated	that	
mast	 cells	 originate	 from	 FcεRI+	 bone	 marrow	 progenitors,	 and	 we	 described	 aberrant	
CD#$RA	expression	on	mast	cells	from	SM	patients.	
In	 study	 IV	 we	 further	 investigated	 the	 cell-forming	 potential	 of	 FcεRI+	 common	 myeloid	
progenitors	 (CMPs)	 in	 the	 bone	 marrow,	 identified	 in	 study	 III.	 We	 found	 distinct	
subpopulations	 within	 the	 FcεRI+	CMPs	 using	 antibodies	 against	CD#$%c	 and	 integrin	 β".	
Culture	 experiments	 showed	 that	 CD#$%c+	 FcεRI+	 CMPs	 differentiate	 into	 mast	 cells	 and	
basophils,	 whereas	 CD#$%c−	 FcεRI+	 CMPs	 form	 mast	 cells,	 basophils,	 and	 erythroid	 cells.	
Granulocyte-monocyte	progenitors,	which	form	neutrophils,	did	not	generate	mast	cells	and	
basophils,	clearly	separating	the	development	of	different	granulocytes.		
Taken	together,	this	thesis	provides	clinical	and	biological	insights	into	mast	cell	development	
in	health	and	systemic	mastocytosis.	
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1 INTRODUCTION	
As	the	title	of	this	thesis	describes,	the	work	of	this	thesis	focuses	on	the	development	of	mast	
cell	in	normal	conditions	and	in	the	mast	cell	disease	called	systemic	mastocytosis	(SM).	The	
introduction	gives	an	overview	of	current	knowledge	on	mast	cells,	mast	cell	precursors	and	
systemic	mastocytosis.	 This	 provides	 the	 necessary	 background	 to	 understand	 the	 findings	
and	discussion	of	the	four	studies	included	this	thesis.	
1.1 THE	IMMUNE	SYSTEM	
All	 organisms	 have	 a	 system	 that	 protects	 itself	 from	 invaders,	 the	 immune	 system.	 In	 this	
thesis	 we	 focus	 on	 the	 mast	 cell,	 a	 tissue-resident	 immune	 cell	 with	 typical	 granules	 first	
described	by	Paul	Enrich.	Evolutionary	primitive	organisms	have	a	similar	granulated	cell	type	
that	circulates	 in	 the	hemolymph	 (figure	 )).	This	 cell	has	granules	 that	contain	heparin	and	
histamine,	similar	to	the	human	mast	cell,	thus	the	cells	are	evolutionary	conserved	(de	Barros	
et	 al.,	 ())*).	 During	 evolution,	 organisms	 became	 more	 complex	 which	 required	 a	 more	
complex	 defence	 system.	Most	 vertebrates	 have	 an	 immune	 system	 that	 consists	 of	 a	 two-
layered	defence	system,	a	first	line	defence,	the	innate	immunity	and	a	second	line	of	defence,	
the	adaptive	immune	system.	Humans	have	more	than	ten	different	types	of	white	blood	cells,	
primarily	 divided	 into	 granulocytes,	 monocytes,	 and	 lymphocytes.	 Some	 immune	 cells	
circulate	through	the	blood	and	can	 leave	to	a	tissue	where	they	detect	a	danger	or	stranger	
signal	 in	 the	human	body.	Other	 immune	cells	 reside	 in	 tissue	where	 they	control	 the	 local	
environment,	providing	 the	 first	 line	of	defence	by	 creating	 a	 site	of	 inflammation	upon	an	
infection.	 Other	 cells	 in	 the	 same	 area	 can	 detect	 the	 same	 antigen	 or	 react	 to	 the	
inflammatory	reaction	of	other	cells	and	migrate	to	lymph	nodes	where	they	pass	it	on	to	the	
second	line	of	defence.	Cell	communication	is	either	direct	by	receptor-ligand	interactions,	or	
indirect	by	the	release	of	certain	factors	locally,	or	at	long	distance	using	small	vesicles.		
	
	
FIGURE	 (.	Electron	microscope	 images	 showing	 electron	 dense	 granules	 in	 a	 primitive	 granulocyte,	
human	tissue-resident	mast	cell	with	a	round	nucleus,	and	human	blood	basophil	with	a	bean-shaped	
nucleus.	 NB.	 Sizes	 are	 not	 directly	 comparable.	 Adapted	 and	 reprinted	 with	 permission	 from	 the	
American	 Society	 For	 Biochemistry	 &	 Molecular	 Biology	 and	 BioMed	 Central	 from	 de	 Barros	 et	 al.	
("##$),	Friesen	et	al.	(-.//)	and	from	Clark	Brelje	and	Sorenson	(histologyguide.org).		
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Together	this	creates	a	very	complex	system	with	a	highly	organized	communication	network.	
Thus,	although	this	thesis	focuses	on	mast	cells,	it	is	important	to	keep	in	mind	that	they	are	
part	of	this	complex	network.	
1.2 HEMATOPOIESIS	
Hematopoiesis	describes	the	development	of	blood	cells,	including	mast	cells.	In	this	thesis	we	
study	human	hematopoiesis	using	primary	cells	and	ex	vivo	culture	systems.	When	studying	
human	 diseases,	 this	 is	 the	 most	 informative	 approach	 because	 it	 is	 more	 relevant	 in	
developing	human	therapeutics	and	accounts	for	species-specific	effects	as	opposed	to	mouse	
strains	that	have	a	similar	genetic	background.	Nevertheless,	in	vivo	mouse	models	are	useful	
for	 studying	 the	effect	of	genetic	 loss	of	 function	and	gain	of	 function	alterations	 related	 to	
human	oncogenesis	and	complement	human	cell	models	when	carried	out	in	parallel.		
In	adults,	all	blood	cells	stem	from	a	common	ancestor	that	resides	in	a	special	niche	in	the	
bone	marrow,	 the	 hematopoietic	 stem	 cell	 (HSC).	 During	 embryogenesis	 there	 is	 no	 bone	
marrow	niche,	 thus	 in	 the	embryo	 the	 first	hematopoietic	cells	arise	 in	 the	extra-embryonic	
yolk	 sac.	 During	 further	 development,	 the	 production	 of	 hematopoietic	 cells	 moves	 to	 the	
aorta-gonad-mesonephros	 region,	 the	placenta,	 the	 fetal	 liver,	 the	 spleen,	 and	 eventually	 to	
the	bone	marrow.	The	bone	marrow	niche	provides	 the	necessary	microenvironment	that	 is	
needed	 for	 HSC	 homeostasis,	 including	 quiescence,	 proliferation,	 self-renewal	 and	
differentiation.	 Besides	 other	 mature	 hematopoietic	 cells,	 the	 niche	 contains	 non-
hematopoietic	 cells	 such	 as	 endothelial	 cells,	 adipocytes,	 supporting	 mesenchymal	 stromal	
cells,	 and	 osteoclasts	 and	 osteoblast.	Local	 signals	 from	 the	microenvironment,	 or	 from	 an	
infection	or	 inflammation	can	influence	and	change	the	HSC	homeostasis,	which	affects	the	
hematopoiesis.	A	genetic	defect	in	one	or	multiple	cells	of	the	hematopoietic	system	can	also	
affect	 the	 development	 of	 hematopoietic	 cells	 and	 cause	 a	myeloid	 or	 lymphoid	 neoplasm	
(Morrison	and	Scadden,	/012;	Ogawa,	/017;	Zon,	/009).	
The	differentiation	of	HSCs	follows	different	trajectories	in	which	the	classical	model	separates	
lymphoid	 cells	 from	 myeloid	 cells	 (figure	 !).	 The	 myeloid	 cells	 include	 all	 granulocytes,	
erythrocyte	progenitors	and	megakaryocytes.	Surface	 receptor	expression,	mRNA	expression	
as	 well	 as	 morphological	 features	 identify	 specific	 progenitors.	 Human	HSCs	 as	 well	 as	 all	
myeloid	and	 lymphoid	progenitors	express	CD/0,	 first	 identified	 in	 3450	(Civin	et	al.,	 -./0).	
Long-term	in	vitro	assays	identify	HSCs	by	their	capability	to	produce	hematopoietic	cells	for	
more	 than	 six	 weeks	 (Spangrude	 et	 al.,	 0122;	 Sutherland	 et	 al.,	 0121).	 Transplantation	 of	
potential	HSCs	into	humanized	immunodeficient	mice	models	further	show	their	capacity	to	
form	all	different	blood	cells,	revealing	their	multipotency	and	long-term	self-renewal	capacity	
(Shultz	et	al.,	-../).	Perhaps	even	better	proof	that	CD!"+	cells	can	replenish	a	whole	body	
with	blood	cells	comes	from	human	allogeneic	HSC	transplants	for	the	treatment	of	lymphoid	
and	myeloid	leukemia.		
Human	HSCs	express	CD#$	(Thy*)	and	CD/#f	(Majeti	et	al.,	,--.;	Notta	et	al.,	)*++).	CD%&	
and	CD'(f	separate	HSCs	from	the	multipotent	progenitor	(MPP),	both	lacking	expression	of	
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CD#$	 and	 CD)*RA.	 This	 change	 in	 expression	 to	 CD:;−	 and	 CD'(f−	MPPs	 represents	 the	
earliest	steps	of	HSC	differentiation.		
Further	 differentiation	 describes	 the	 segregation	 into	 a	 common	 myeloid	 and	 common	
lymphoid	 progenitor.	 The	 common	 myeloid	 progenitor	 (CMP),	 branches	 down	 into	
megakaryocyte-erythroid	progenitors	(MEPs)	and	granulocyte-monocyte	progenitors	(GMPs)	
(Manz	 et	 al.,	 ,--,).	 These	 cell	 progenitor	 populations	 express	 CD)*	 and	 have	 differential	
expression	of	CD-./,	and	CD34RA	(Manz	et	al.,	,--,).	
Later	studies	showed	that	not	all	myeloid	cells	develop	through	a	common	myeloid	progenitor	
(Görgens	 et	 al.,	 /012).	 Lymphocytes,	 monocytes	 and	 neutrophils	 differentiate	 though	 the	
lymphoid-myeloid	 primed	 progenitor	 (LMPP)	 (Goardon	 et	 al.,	 '()))	 (figure	 !;	 hierarchical	
model).	 Megakaryocytes,	 erythrocytes,	 and	 other	 myeloid	 cells	 such	 as	 basophils	 and	
eosinophils	 differentiate	 through	 the	 common	 erythroid-myeloid	 progenitor	 (EMP).	 LMPPs	
give	 rise	 to	 lymphocytes	 and	 NK	 cells	 through	 the	 multi-lymphoid	 progenitor	 (MLP)	
(Doulatov	et	al.,	-./.).	In	the	LMPP-EMP	model,	the	GMP	gives	monocytes	and	neutrophils,	
but	not	 other	 granulocytes,	which	 is	 important	 to	 remember	when	using	 the	nomenclature	
“GMP”.	 Furthermore,	 this	 model	 also	 suggests	 the	 existence	 of	 an	 eosinophil-basophil	
progenitor	(EoBP),	as	shown	before	(Denburg	et	al.,	/012).	Eosinophils	and	basophils	grow	in	
vitro	 cultures	 supplemented	with	 IL-!	 and	 IL-!	 (Boyce	 et	 al.,	 -../).	 The	 IL-!	 receptor	 (IL-
!R/CD&'!)	 is	 a	 marker	 for	 eosinophils	 and	 eosinophil	 progenitors	 (Mori	 et	 al.,	 -../).	
Similarly,	IL-!	binds	to	the	IL-!	receptor	(IL-!R/CD&'!),	which	 is	the	main	growth	factor	for	
basophils	 (Valent	 et	 al.,	 +,-,).	 In	 addition,	 CD-.	 and	 CD/0-c	 are	 present	 on	 basophil	
progenitors,	 but	 cultured	 CD34+	 CD#$%c+	 cells	 do	 not	 exclusively	 give	 rise	 to	 basophils	
(Buhring	 et	 al.,	 0111).	 Thus,	 there	 are	 some	 potential	 markers	 that	 can	 identify	 basophil	
progenitors,	but	a	unipotent	basophil	progenitor	is	still	to	be	isolated.		
	
FIGURE	(.	Human	adult	hematopoietic	stem	cells	reside	in	a	special	niche	in	the	bone	marrow	and	
differentiate	into	lymphoid	and	myeloid	cells.	
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The	LMPP-EMP	model	does	not	describe	mast	cells,	which	circulate	in	the	blood	as	mast	cell	
progenitors	(MCPs)	(Dahlin	et	al.,	-./0).	However	mast	cells	likely	develop	from	EMPs,	rather	
than	LMPPs	because	of	their	similarity	to	basophils,	also	packed	with	electron-dense	granules	
(figure	)).	Mast	cells	and	basophils	both	express	the	high-affinity	IgE	receptor,	FcεRI,	whereas	
expression	of	the	receptor	for	stem	cell	factor	(SCF),	KIT	(CD;;<)	distinguishes	mast	cells	from	
basophils.	Hematopoietic	cells	express	KIT	throughout	development	and	mast	cells	upregulate	
KIT	 when	 they	mature,	 whereas	 basophils	 and	most	 other	 blood	 cells	 lose	 KIT	 expression	
(Irani	 et	 al.,	 -../).	Whereas	 eosinophils,	 basophils,	 and	mast	 cells	 have	 some	 phenotypical	
similarities,	 transcriptional	 data	 clearly	 shows	 that	 mast	 cells,	 basophils,	 and	 eosinophils	
present	a	unique	transcriptional	signature	(Dwyer	et	al.,	-./0;	Motakis	et	al.,	-./7).	
The	 application	 of	 single-cell	 sequencing	 techniques	 in	hematopoiesis	 research	 changes	 the	
view	 on	 the	 process	 of	 blood	 cell	 development	 further,	 questioning	 the	 existence	 of	 a	
hierarchical	model	of	hematopoiesis.	It	is	becoming	increasingly	clear	that	hematopoiesis	is	a	
gradual	process	without	stable	intermediate	progenitors	(figure	!;	gradual	model)	(Notta	et	al.,	
!"#$;	Paul	et	al.,	!"#/;	Tusi	et	al.,	!"#3;	Velten	et	al.,	!"#6;	Zheng	et	al.,	!"#3).	In	the	gradual	
model	 for	 hematopoiesis,	 the	 phenotypic	 progenitors	 from	 the	 classical	 models	 do	 not	
constitute	 discrete	 progenitor	 cells	 types,	 but	 rather	 a	 transitory	 state.	 This	 means	 that	
different	 cell	 lineage	 can	 emerge	 directly	 from	 the	HSC,	without	 passing	 through	 separate,	
stable	 progenitors.	 However	 in	 this	 model,	 intermediate	 progenitors	 can	 still	 be	 identified	
which	describe	differentiating	progenitors	that	have	a	restricted	potential.	
1.3 MAST	CELL	DIFFERENTIATION	
Mast	cells	develop	from	a	hematopoietic	precursor,	but	are	often	overlooked	in	hematopoiesis	
models	because	mast	cells	reside	in	the	tissue.		
	
FIGURE	!.	Two	models	describing	hematopoiesis,	traditionally	depicted	in	a	hierarchy	model,	but	
recently	revised	into	a	gradual	model.	Adapted	from	(Grootens	et	al.,	./01).		
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Mice	 studies	 showed	 for	 the	 first	 time	 that	mast	 cells	 arise	 from	 bone	marrow	progenitors	
(Kanakura	et	al.,	./00;	Kitamura	et	al.,	./44)	and	from	early	precursors	in	the	embryo	(Sonoda	
et	al.,	()*+;	Tsai	and	Orkin,	())5).	Mast	cells	derived	from	the	embryonic	yolk	sac	are	the	first	
skin	and	connective	tissue	mast	cells	in	the	embryo	(Gentek	et	al.,	,-./;	Li	et	al.,	,-./).	Bone	
marrow-derived	mast	 cells	gradually	 replace	 yolk	 sac-derived	mast	 cells	 in	 adults.	Whether	
mast	 cells	 derive	directly	 from	 the	HSC	or	 through	 intermediate	 progenitors	has	 long	been	
discussed.	The	bone	marrow	in	mice	contains	committed	mast	cell	progenitors	(Chen	et	al.,	
!""#;	 Jamur	 et	 al.,	 !""#),	 as	 well	 as	 bipotent	 progenitor	 basophils-mast	 cell	 progenitors	
(BMCPs),	first	shown	in	spleen	(Arinobu	et	al.,	0112)	and	recently	in	bone	marrow	(Dahlin	et	
al.,	&'()).		
So	far,	a	unipotent	MCP	has	not	been	defined	in	the	human	bone	marrow.	However,	cultures	
of	human	CD)*+	bone	marrow	progenitor	give	rise	to	mast	cells	in	vitro	(Kirshenbaum	et	al.,	
!""!)	and	in	vivo	(Födinger	et	al.,	0112).	As	mentioned	before,	basophils	develop	from	sorted	
CD#$+	 CD#$%c+	 cell	 from	 the	 bone	 marrow	 when	 cultured	 in	 multilineage	 stimulating	
medium,	 however	 addition	 of	 SCF	 also	 gives	 mast	 cell	 colonies	 as	 well	 as	 eosinophil	 and	
macrophage/neutrophil	colonies	(Buhring	et	al.,	0111).	In	addition,	CD#$%c−	sorted	cells	also	
give	mast	 cell	colonies,	 suggesting	 that	 this	marker	 is	not	 specific	 for	mast	 cell	progenitors.	
Furthermore,	CD#$+	CD##$+	CD#$+	progenitors	from	the	bone	marrow	give	mast	cell-monocyte	
colonies	(Kirshenbaum	et	al.,	2333).		
Circulating	 CD-.+	 progenitors	 in	 the	 peripheral	 blood	 also	 give	 rise	 to	 mast	 cells	 when	
cultured	 in	vitro,	 further	 specified	 to	be	a	mast	cell	progenitor	 (MCP)	 that	expresses	CD;<+	
CD""#int/hi	FcεRI+	and	comprise	about	'.'')%	of	blood	mononuclear	cells	(Dahlin	et	al.,	-./0;	
Maaninka	 et	 al.,	 ,-./).	MCPs	 lack	 expression	 of	 CD12RA,	which	 places	 them	 in	 the	 classic	
CMP	gate,	but	this	does	not	necessarily	mean	that	they	are	derived	from	the	CMP.	The	classic	
CMPs	 gate	 is	 likely	 not	 identifying	 one	 progenitor	 state,	 as	 others	 also	 identified	 a	
subpopulation	with	 eosinophil	 progenitors	 within	 the	 CMP	 population	 (Mori	 et	 al.,	 -../).	
Surface	expression	of	 integrin	β"	on	MCPs	regulates	migration	from	the	blood	to	peripheral	
tissues,	where	mature	mast	cells	take	lifelong	residence	(Gurish	et	al.,	/001).	
Human	umbilical	cord	blood	provides	another	source	to	study	mast	cell	development.	Cord	
blood	contains	more	multilineage	progenitors	compared	with	adult	bone	marrow	(Notta	et	al.,	
!"#$).	However,	conserved	key	regulators	 in	both	tissues,	makes	 it	an	 interesting	source	 for	
progenitor	 studies	 (Zheng	 et	 al.,	 -./0).	 Single-cell	 culture	 experiments	 of	 cord	 blood	
progenitors	 suggest	 that	 MCPs	 are	 enriched	 in	 the	 CD01+	 CD#$+	 HLA-DR−	 cell	 fraction.	
However,	 depending	 on	 the	 added	 cytokines	 mast	 cells	 colonies	 also	 develop	 from	CD#$+	
HLA-DR+	and	CD'(+	CD#$−	fractions	(Kempuraj	et	al.,	/000).		
As	 mentioned,	 the	 transcriptional	 profile	 of	 mature	 mast	 cells	 is	 unique	 compared	 with	
basophils.	Whole	transcriptome	analysis	of	blood	MCPs	shows	the	expression	of	several	mast	
cell-associated	 genes,	 including	 tryptase,	 carboxypeptidase,	 and	 serglycin,	 which	 are	 not	
highly	expressed	in	basophils	(Dahlin	et	al.,	-./0).		
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1.4 IN	VITRO	MAST	CELL	DIFFERENTIATION	
In	 vitro	 differentiation	 of	 mast	 cells	 provides	 more	 insight	 into	 necessary	 cytokines	 and	
growth	factor	signaling.	Established	culture	protocols	typically	start	with	enriched	CD,-+	cells	
from	peripheral	blood	or	cord	blood	and	give	mature	mast	cells	after	5-!	weeks	of	culture.	It	is	
well	 established	 that	 SCF,	 the	 ligand	 for	 the	 KIT	 receptor,	 is	 important	 for	 obtaining	 fully	
maturate	human	mast	 cells	 (Irani	 et	 al.,	 -../;	Kirshenbaum	 et	 al.,	 -../;	Mitsui	 et	 al.,	 -..8;	
Valent	 et	 al.,	 *++,).	 The	 combination	 of	 SCF	 with	 IL-!,	 binding	 to	 the	 IL-!	 receptor	 (IL-
!R/CD&'!)	 gives	 significant	 more	mast	 cells	 after	 /	 weeks	 of	 culturing	 (Saito	 et	 al.,	 ,--.).	
However,	others	showed	a	reduction	in	mast	cell	numbers	when	cultured	with	IL-!	and	SCF	
(Kinoshita	 et	 al.,	 /000).	 The	 combination	 of	 SCF	 with	 IL-!,	 binding	 to	 the	 IL-!R	 (CD#$%),	
shows	beneficial	effects	on	the	culture	outcome,	whereas	IL-!	alone	does	not	give	mature	mast	
cells	 with	 tryptase-expressing	 granules	 (Irani	 et	 al.,	 -../;	 Kirshenbaum	 et	 al.,	 -../).	 The	
changes	in	the	surface	expression	of	several	markers	provide	a	method	to	follow	in	vitro	mast	
cell	maturation	from	CD01+	cells.	Cultures	of	CD./+	progenitors	from	cord	blood	in	medium	
with	SCF	and	IL-!	results	in	reduced	expression	of	CD01,	CD340,	and	CD460c	over	the	course	
of	 #	 weeks.	 In	 contrast	 CD-.	 expression	 increases	 and	 is	 highly	 expressed	 after	 0	 weeks	
(Schernthaner	et	al.,	.//0).	Addition	of	 IL-!	results	 in	upregulation	of	 functional	FcεRI	and	
complement	 receptors	CR.	 (CD12)	 and	C2aR	 (CD66)	 (Schernthaner	 et	 al.,	 .//0;	Xia	 et	 al.,	
!""#).	Therefore	IL-!	is	commonly	added	during	the	last	days	of	culture	in	order	to	get	higher	
FcεRI	 expression	 for	 studying	 mast	 cell	 activation.	 However,	 prolonged	 exposure	 to	 IL-!	
downregulates	CD001	and	inhibits	mast	cell	development	(Nilsson	et	al.,	.//0b)	
Other	 mast	 cell	 culture	 protocols	 start	 with	 different	 pre-selected	 cells,	 such	 as	 CD#$$+	
progenitors	 from	 cord	 blood.	 After	 '(	 weeks,	 the	 cultured	mast	 cells	 express	 CD++,,	 CD+.,	
CD##,	 and	 FcεRI,	 but	 also	 cytokine	 receptors	 CD678,	 IL-!R,	 and	 GM-CSFR,	 expressed	 on	
eosinophils	and	basophils	(Dahl	et	al.,	+,,-).	Following	the	redefined	hematopoiesis	models,	
CD#$$+	expression	is	specific	for	MPPs	and	the	lymphoid-myeloid	lineage,	whereas	erythroid-
myeloid	 lineages	 that	 develop	 into	 eosinophils	 and	 basophils,	 and	 likely	 mast	 cells,	 are	
CD#$$low	cells	(Görgens	et	al.,	/01!).	Thus,	mast	cells	that	differentiate	in	this	culture	protocol	
arise	from	an	early	progenitor	as	this	protocol	discards	CD#$$low	progenitors.	
1.5 MAST	CELL	FUNCTION	
The	 most	 studied	 function	 of	 mature	 mast	 cells	 is	 their	 response	 through	 IgE-mediated	
degranulation.	Crosslinking	by	an	allergen	of	two	IgE	molecules	that	are	interacting	with	two	
FcεRI	molecules	results	in	the	activation	of	downstream	pathways	and	release	of	the	content	
of	 the	 granules.	 Mast	 cells	 also	 get	 activated	 independently	 of	 IgE,	 through	 complement	
receptors,	 toll-like	 receptors,	 or	 other	 inflammatory	 cytokines	 such	 as	 chemokines	 and	
interleukins.	
Mast	cell	granules,	also	called	secretory	lysosomes,	form	in	the	cytoplasm	of	the	cell.	They	bud	
of	 from	 intracellular	 compartments	 such	 as	 the	 lysosomes,	 and	 therefore	 carry	 different	
proteins	in	the	membrane	compared	to	the	cell	surface.	As	a	consequence,	when	the	granule	
fuses	 with	 the	 cell	 surface	 membrane,	 this	 increases	 cell	 surface	 expression	 of	 certain	
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tetraspanins	 such	 as	 CD/0	 (Knol	 et	 al.,	 ,--,).	 IgE	 crosslinking	 of	 FcεRI	 on	 mast	 cells	 also	
results	in	upregulation	of	CD123c	(Hauswirth	et	al.,	0112).	CD#$	and	CD)*$c	are	commonly	
used	as	basophil	activation	markers	(Ocmant	et	al.,	())*).		
Mast	cell	granules	contain	several	pre-stored	mediators,	including	amines	(e.g.	histamine	and	
serotonin),	 proteases	 (e.g.	 tryptase,	 chymase),	 lysosomal	 enzymes	 (e.g.	 β-hexosaminidase),	
cytokines	(e.g.	TNF,	IL-!)	and	proteoglycans	(e.g.	heparin).	Mast	cells	release	these	mediators	
in	a	 first	 and	 immediate	 response	within	 seconds	 to	minutes	after	 activation.	Subsequently,	
mast	 cells	 release	 enzymatically	 synthesized	 lipid	 mediators	 (e.g.	 leukotriene	 C8,	
prostaglandin	D.	and	platelet	activating	factor).	 In	a	delayed	response,	mast	cells	release	de	
novo	 synthesized	 proteins	 including	 cytokines,	 chemokines,	 growth	 factors	 and	 interferons	
(Moon	 et	 al.,	 ,-./).	 Depending	 on	 what	 the	 mast	 cells	 recognize,	 they	 release	 different	
mediators.	Activation	 through	 FcεRI	 results	 in	 degranulation	 and	 the	 subsequent	 release	 of	
mediators,	whereas	activation	through	for	example	toll-like	receptors	leads	to	the	production	
and	 release	 of	 cytokines	 and	 chemokines.	 After	 degranulation,	 mast	 cells	 produce	 new	
granules	and	continue	 to	survey	 in	 the	specific	 tissue	of	 their	 residence	(Xiang	et	al.,	-../).	
Mast	 cells	 often	 reside	nearby	 blood	 vessels	 where	 they	 can	 increase	 vascular	 permeability	
through	mediators	such	as	histamine	and	VEGF	(Abraham	and	St	John,	0121).	Mast	cells	also	
play	a	role	in	smooth	muscle	cells	contraction	in	organs	as	the	respiratory	and	gastrointestinal	
tract	 and	 exist	 in	 the	 nervous	 system	 (Abraham	 and	 St	 John,	 0121).	 All	 these	 processes	
mediated	 by	 the	 release	 of	 mast	 cell	 mediators	 are	 important	 for	 pathogen	 surveillance,	
antipathogen	reactions	and	other	mechanisms	of	eliminating	microorganisms	from	the	host	as	
an	 innate	 immune	response.	 Interestingly,	mast	cells	can	also	activate	 the	adaptive	 immune	
system	directly	 by	 presenting	 antigens	 to	 T-lymphocytes,	 and	 indirectly	 by	 activating	 other	
antigen	presenting	cells	such	as	dendritic	cells	(Carroll-Portillo	et	al.,	,-./;	Lotfi-Emran	et	al.,	
!"#$).	
1.6 THE	KIT	RECEPTOR	
The	 KIT	 receptor	 is	 part	 of	 the	 family	 of	 type	 III	 receptor	 tyrosine	 kinases	 that	 includes	
macrophage	colony-stimulating	factor	/	receptor	(CSF-!R),	the	platelet-derived	growth	factor	
receptor	 (PDGFR),	 and	 the	 FMS-like	 tyrosine	 kinase	 -	 (FLT-).	 These	 cell-surface	 receptors	
have	 a	 similar	 structure,	 including	 an	 extracellular	 immunoglobin-like	 domain,	 a	
transmembrane	 domain,	 the	 juxtamembrane	 region	 and	 the	 cytoplasmic	 kinase	 domains.	
Activation	 of	 the	 receptor	 through	 ligand	 binding	 is	 a	 tightly	 regulated	 process,	 triggering	
dimerization,	 kinase	 activation,	 and	 phosphorylation	 of	 downstream	 targets	 (Schlessinger,	
!""").	As	mentioned,	the	KIT	receptor	is	important	for	mast	cell	differentiation.	Other	mast	
cell	functions	regulated	by	KIT	and	SCF	are	migration	(Nilsson	et	al.,	.//0a),	survival	(Moller	
et	 al.,	 ())*),	 adhesion	 (Dastych	 and	 Metcalfe,	 1223),	 and	 potentiation	 of	 FcεRI	 activation	
(Bischoff	and	Dahinden,	 0112).	Non-mast	cell	mediated	processes	that	require	KIT	signaling	
are	 pigmentation,	 reproduction,	 gut	 motility,	 functioning	 nervous	 system,	 cardiovascular	
system,	and	lung	tissue	integrity	(Lennartsson	and	Ronnstrand,	./0.).	
Binding	 of	 SCF	 results	 in	 dimerization	 of	 the	 receptor	 and	 subsequent	 activation	 of	 the	
intracellular	 kinase	 domains	 (figure	 !).	 KIT	 activation	 results	 in	 a	 conformational	 change	
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enabling	activation	of	other	signaling	molecules	that	initiate	intracellular	signal	transduction	
pathways.	 Downstream	 signal	 transduction	 pathways	 of	 KIT	 create	 a	 complex	 signaling	
network.	 Activated	 pathways	 include	 the	 PI#-kinases/mTOR	 pathway,	 JAK-STAT	 signaling,	
and	 MAP	 Kinase	 pathways.	 These	 pathways	 function	 in	 mast	 cell	 survival,	 proliferation,	
activation,	 and	 migration	 (Lennartsson	 and	 Ronnstrand,	 ./0.).	 Expression	 of	 oncogenic	
mutations	 in	 KIT	 causes	 SCF-independent	 phosphorylation	 and	 potentiates	 several	 human	
malignancies,	including	systemic	mastocytosis,	which	is	introduced	in	the	next	section.	More	
than	&''	different	mutations	are	described	in	the	KIT	gene,	of	which	most	located	in	exon	..	
and	 %&	 (Lennartsson	 and	 Ronnstrand,	 ./0.).	 However,	 the	 exact	 mechanism	 behind	
constitutive	KIT	activation	is	not	fully	understood.	
1.7 SYSTEMIC	MASTOCYTOSIS		
SM	 is	 a	 rare	 disease	and	 classified	as	myeloid	 neoplasm	by	 the	World	Health	Organization	
(WHO).	The	primary	actors	 in	 this	disease	are	clusters	of	aberrant,	or	neoplastic	mast	cells.	
Increase	 in	mast	 cell	mediators	are	 the	cause	 several	of	 the	 symptoms	 these	 patients	 suffer	
from.	 Symptoms	 include	 flushing,	 headache,	 dizziness,	 abdominal	 pain,	 diarrhea,	 fatigue	or	
anaphylaxis	 (Gülen	 et	 al.,	 ,-./).	 Symptoms	 are	 often	 not	 only	 physical	 since	 most	 of	 the	
patients	 experience	 a	 psychosocial	 influence	 in	 their	 daily	 live,	 reflecting	 on	 their	
relationships,	work,	and	family	(Jensen	et	al.,	,-./).	
	
FIGURE	!.	Schematic	 structure	of	 the	KIT	 receptor.	Binding	of	 SCF	 results	 in	dimerization,	 tyrosine	
kinase	 (TK)	 activation	 and	 subsequent	 phosphorylation	 of	 the	 eight	 tyrosines	 (Tyr)	 that	 induces	
downstream	signaling	pathways.	The	mutation	D678V	results	in	activation	without	binding	of	SCF.		
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The	most	visible	 symptoms	are	 typical	brown	or	 red	 lesions	 in	 the	skin	caused	by	mast	cell	
clustering.	Mast	cells	can	also	accumulate	in	other	organs,	including	the	bone	marrow,	spleen,	
liver,	intestine,	or	lymph	nodes.	Infiltration	of	the	skin	only	is	named	cutaneous	mastocytosis	
(CM)	 and	 the	 accumulation	 of	 mast	 cells	 in	 other	 organs	 is	 named	 systemic	 mastocytosis	
(SM).	 A	 third	 rare	 subcategory	 identifies	 localized	mast	 cell	 tumors	 or	 mast	 cell	 sarcomas	
(Valent	et	al.,	+,!").	The	prevalence	of	mastocytosis	is	estimated	at	5.6-!	per	!&,&&&	adults	in	
central	Europe	(Cohen	et	al.,	-./0;	van	Doormaal	et	al.,	-./6).		
1.7.1 DISEASE	CLASSIFICATION	
The	WHO	provides	guidelines	for	classification	of	subtypes	within	the	three	main	variants	of	
mastocytosis	 (Arber	et	al.,	,-./).	CM	is	more	 frequently	 seen	 in	children	and	resolves	often	
spontaneously	 around	 puberty	 (Hartmann	 et	 al.,	 *+,-).	 The	 type	 of	 skin	 lesions,	 the	
distribution,	and	the	disease	onset	further	classifies	CM	into	maculopapular	CM	(also	known	
as	urticaria	pigmentosa),	diffuse	CM,	and	mastocytoma	of	the	skin	(figure	!).	Maculopapular	
lesions	are	the	most	common	form	and	are	present	in	about	'(%	of	patients	with	adulthood-
onset	 of	mastocytosis.	 In	 adults,	 lesions	 usually	 start	 to	 develop	 around	 the	 thigh	 and	 can	
spread	to	other	body	parts	over	the	years.	Most	adult	patients	have	mast	cells	infiltrates	in	the	
bone	marrow,	which	corresponds	to	the	systemic	disease.	The	major	criterion	for	SM	describes	
dense	 infiltrates	of	mast	cells.	Minor	criteria	describe	more	specific	characteristics	 including	
spindle	shaped	mast	cells,	a	mutation	in	the	KIT	receptor,	aberrant	CD#/CD#%	expression	on	
mast	 cells,	 and	 increased	 serum	 tryptase	 (table	 ').	B-and	C-findings	 further	 divide	 SM	 into	
indolent	 SM	 (ISM),	 smoldering	 SM	 (SSM),	 SM	with	 an	 associated	 hematological	 neoplasm	
(SM-AHN),	aggressive	SM	(ASM)	and	mast	cell	leukemia	(MCL)	(table	().	
Immunohistochemistry	 staining	 for	CD-.	 and	 tryptase	 identifies	 aberrant	mast	 cells	 (figure	
!).	 ISM	 is	 the	most	prevalent	 subtype	of	 SM	and	 symptoms	are	mainly	mast	 cell	mediator-
related	 without	 organ	 dysfunction.	 ISM	 patients	 are	 significantly	 younger	 at	 diagnosis	
compared	with	patients	with	more	 severe	 subtypes	 and	usually	 have	more	 skin	 lesions	 and	
gastrointestinal	 symptoms.	The	overall	 survival	of	 ISM	patients	 is	not	different	compared	to	
the	healthy	population	(Lim	et	al.,	,--.).	SSM	is	more	severe	compared	with	ISM	shown	by	
inferior	survival,	but	more	favorable	compared	with	ASM	and	MCL	(Tefferi	et	al.,	-./0).	SSM	
is	 identified	by	B-findings,	whereas	C-findings	 identify	ASM	and	MCL	(table	2).	 In	addition,	
SM	patients	can	present	an	associated	hematologic	neoplasm	(AHN).	
	
FIGURE	!.	Cutaneous	forms	of	mastocytosis	are	categorized	into	maculopapular	(A),	diffuse	(B),	and	
mastocytoma	(C).	Reprinted	with	permission	from	Elsevier,	original	from	Hartmann	(+,-.).		
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TABLE	'.	WHO	criteria	for	diagnostics	of	patients	suspected	of	systemic	mastocytosis.	The	diagnosis	is	
SM	when	patients	have	at	least	'	major	and	'	minor,	or	0	minor	criteria	(Valent	et	al.,	!"#$).	
Criterion	 Description	
Major	 More	than	one	dense	infiltrate	of	mast	cells	(>!")	in	at	least	one	tissue	that	is	
not	skin,	by	immunohistochemistry	
Minor	 >!"%	of	the	mast	cells	are	spindle-shaped		
Presence	of	the	KIT	mutation	D*+,V	in	bone	marrow	or	peripheral	blood		
Mast	cells	express	CD!	and/or	CD!"		
Elevated	total	serum-tryptase	levels	of	>!"	ng/ml	
	
	
	
TABLE	'.	WHO	definition	and	criteria	of	B-findings	and	C-findings	in	SM.	Diagnosis	with	the	presence	
of	!	B-findings	and	no	C-findings	is	ISM,	more	than	&	B-findings	and	no	C-findings	is	SSM,	whereas	
more	than	*	C-finding	is	ASM	or	MCL	(Valent	et	al.,	+,-.).	
Criterion	 Description	
B-findings	 Indicate	a	high	burden	of	mast	cells	and	expansion	of	the	neoplastic	process	
into	multiple	hematopoietic	lineages,	without	visible	impairment	of	organ	
function	
! Mast	cell	infiltration	grade	in	the	bone	marrow	>23%	by	histology	and	
the	basal	serum	tryptase	level	is	>!""	ng/mL	
! Hypercellular	bone	marrow	with	loss	of	fat	cells,	discrete	signs	of	
dysmyelopoiesis	without	substantial	cytopenias	or	WHO	criteria	for	
an	MDS	or	MPN	
! Organomegaly:	palpable	hepatomegaly,	palpable	splenomegaly,	or	
palpable	lymphadenopathy	(>!	cm)	without	impaired	organ	function	
C-findings	 Are	indicative	of	organ	damage	produced	by	mast	cell	infiltration	
! Cytopenia(s):	absolute	neutrophil	count	<1,000/µL	or	hemoglobin	
<10	g/dL	or	platelet	count	<100,000/µL	
! Hepatomegaly	with	ascites	and	impaired	liver	function	
! Palpable	splenomegaly	with	associated	hypersplenism	
! Malabsorption	with	hypoalbuminemia	and	weight	loss	
! Skeletal	lesions:	large-sized	osteolyses	with	pathologic	fractures	
! Life-threatening	organ	damage	in	other	organ	systems	that	is		
caused	by	local	mast	cell	infiltration	in	tissues	
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AHNs	 are	 most	 frequently	 other	 myeloid	 neoplasm	 such	 as	 myelodysplastic	 syndromes	
(MDS),	 chronic	 myelomonocytic	 leukemia	 (CMML),	 forms	 of,	 or	 acute	 myeloid	 leukemia	
(AML),	or	myeloproliferative	neoplasms	(MPNs),	but	can	also	include	lymphoid	hematological	
malignancies	 (Valent	 et	 al.,	 +,-.).	 A	 reduced	median	 survival	 of	 #-!	 years	 after	 diagnosis	
marks	 more	 advanced	 subtypes,	 whereas	 median	 survival	 in	 MCL	 is	 only	 &	 months	 after	
diagnosis	(Lim	et	al.,	,--.).	
The	third	mastocytosis	category	describes	the	presence	of	mast	cell	sarcomas,	manifesting	as	
an	isolated	destructive	mass.	These	tumors	are	extremely	rare	with	about	ten	cases	reported	in	
the	literature.	Their	limited	resemblance	to	normal	mast	cells	makes	identification	and	correct	
diagnosis	rather	difficult.	In	addition,	patients	with	mast	cell	sarcoma	do	not	fulfill	the	major	
criteria	and	usually	do	not	carry	the	same	mutation	in	KIT	as	most	SM	patients	(Ryan	et	al.,	
!"#$).	
1.7.2 ABERRANT	MAST	CELL	MEDIATORS	
As	 mentioned,	 patients	 with	 ISM	 experience	 symptoms	 that	 are	 the	 result	 of	 mast	 cell	
mediator	release,	with	the	most	severe	reaction	being	an	anaphylactic	reaction.	A	study	among	
!"	Stockholm	patients	 including	different	SM	subtypes	showed	that	%&	of	$%	(%'%)	patients	
experience	 at	 least	 one	 anaphylactic	 episode,	 mainly	 caused	 by	 wasp	 stings	 (Gulen	 et	 al.,	
!"#$).	Several	mediators	show	a	degree	of	elevation	in	SM	patients,	of	which	a	serum	tryptase	
level	 >!"	 ng/mL	 is	 the	 only	 one	 that	 indicates	 a	 minor	 diagnostic	 criterion.	 The	 serum	
tryptase	 levels	 correlates	 with	 the	 percentage	 of	 mast	 cell	 infiltrates	 in	 the	 bone	 marrow	
(Schwartz	et	al.,	/001;	Sperr	et	al.,	4554).	In	addition,	high	serum	tryptase	is	associated	with	
poor	prognosis	and	subsequent	disease	progression	 (Matito	et	al.,	,-./).	Other	diseases	can	
also	present	increased	tryptase	levels,	such	as	MDS,	MPN,	AML,	CML	or	renal	failure	(Sirvent	
et	al.,	()*);	Valent	et	al.,	()*.).	Another	prominent	mast	cell	mediator	found	in	the	majority	
of	SM	patients	is	serum	IL-!	(Brockow	et	al.,	/00/;	Theoharides	et	al.,	/00/).	IL-!	presents	an	
early	marker	for	disease	progression	in	ISM	(Mayado	et	al.,	-./0).	Furthermore,	a	recent	study	
showed	that	aberrant	signaling	of	oncogenic	KIT	induces	IL-!	production	(Tobío	et	al.,	-./0).	
	
FIGURE	!.	Immunohistochemistry	staining	of	bone	marrow	biopsies	showing	mast	cell	infiltrates	using	
CD#$,	and	tryptase	in	the	same	biopsy.	Photo	credits	Igor	Schliemann,	Karolinska	University	Hospital.	
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Other	known	mast	 cell	mediators	 in	SM	are	histamine	 and	 several	 lipid	mediators,	 such	 as	
prostaglandins	and	leukotrienes	and	platelet	activating	factor	(Butterfield	et	al.,	/012).	
1.7.3 EXPRESSION	PROFILE	OF	ABERRANT	MAST	CELLS	
Mast	cells	in	SM	often	present	aberrant	protein	expression,	detectable	by	flow	cytometry,	also	
used	in	the	clinic	as	complementary	method	to	immunohistochemistry.	For	example,	CD889	is	
informative	 as	 immunohistochemistry	marker	 to	detect	mast	 cell	 clusters	 in	 tissue	biopsies,	
providing	essential	 information	on	disease	progression.	Flow	cytometry	 analysis	of	CD334	 in	
combination	 with	 FcεRI	 provides	 the	 percentage	 of	 mast	 cells	 in	 a	 bone	 marrow	 aspirate.	
Comparing	 surface	 expression	 of	 these	 markers	 in	 SM	 subtypes	 showed	 comparable	
expression	 of	 CD##$	 and	 FcεRI	 in	 ISM,	 SM-AHN,	 and	 controls	 (Teodosio	 et	 al.,	 +,-,).	
However,	lower	expression	of	CD223	and	FcεRI	is	often	observed	in	MCL	and	ASM.		
In	the	last	two	decades,	multiple	aberrant	markers	are	identified	on	SM	mast	cells	in	the	bone	
marrow	using	flow	cytometry.	These	markers	are	absent	or	expressed	at	low	levels	on	normal	
bone	 marrow	 mast	 cells	 (figure	 !).	 Currently	 only	 CD.	 and	 CD.1	 contribute	 to	 diagnosis	
(Escribano	et	al.,	1223;	Jabbar	et	al.,	1236;	Teodosio	et	al.,	1239).	
Diagnostic	markers.	CD#	and	CD%&	(IL-!Rα)	are	the	first	specific	markers	described	for	SM	in	
a	cohort	of	)*	ISM	patients	(Escribano	et	al.,	1223b).	Whereas	CD+,	is	commonly	present	on	
aberrant	mast	cells	in	SM	patients,	aberrant	CD3	expression	is	not	always	present,	particularly	
in	AdvSM,	making	it	a	less	reliable	maker	compared	with	CD#$	(Morgado	et	al.,	./0.).	Both	
antigens	are	commonly	known	as	lymphoid	markers,	CD7	as	early	marker	for	T	cells,	whereas	
CD#$	 is	 a	marker	 for	 regulatory	T	 cells	 and	 activated	T	 cells.	 Interestingly,	 CD#	 and	CD#$	
expression	is	not	specific	for	mast	cells	in	SM	since	mast	cells	in	a	subset	of	patients	without	
any	history	of	SM	also	express	CD,	and	CD,/.	These	patient	however,	have	other	neoplasms	
including	lymphoblastic	leukemia	and	plasma	cell	neoplasm	(Cherian	et	al.,	./01).	
Advanced	 SM	 markers.	 Another	 lymphoid	 marker	 expressed	 by	 neoplastic	 cells	 in	 some	
lymphoid	 neoplasms	 is	 CD01	 (Ki-!	 antigen)	 (Sotlar	 et	 al.,	 '())).	 In	 SM,	CD*+	 expression	 is	
specific	for	mast	cells	in	AdvSM	patients,	providing	a	biomarker	of	aggressive	disease	variants.	
Similarly,	CD,-	expression	marks	neoplastic	mast	 cells	of	AdvSM	patients,	but	 is	absent	on	
normal	and	ISM	mast	cells	(Hoermann	et	al.,	./01a).	
Activation	 markers.	 Expression	 of	 several	 activation	 markers	 on	 neoplastic	 mast	 cells	may	
reflect	 the	 increase	 in	activation	of	 the	mast	cells.	SM	patients	have	 increased	CD23	surface	
expression	on	mast	cells	(Escribano	et	al.,	1223a).	Increase	in	CD#$%c	expression	on	neoplastic	
mast	cells	 is	highest	 in	 ISM	 (Hauswirth	et	al.,	0112).	Additionally,	SM	patients	have	higher	
expression	of	CD-.,	but	this	varies	between	patients	(Diaz-Agustin	et	al.,	.///;	Jabbar	et	al.,	
!"#$).	CD%&	 is	a	T-cell	activation	maker	that	 is	also	expressed	on	basophils	and	eosinophils	
upon	 degranulation,	 similar	 to	 CD./	 but	 with	 a	 slower	 response	 (Yoshimura	 et	 al.,	 1221).	
Another	T	cell	and	eosinophil	activation	marker,	CD%%,	 is	 increased	on	mast	cells	of	all	SM	
subtypes	(Matsumoto	et	al.,	.//0;	Sano	et	al.,	.//0).	In	addition,	the	level	of	soluble	CD++	is	
higher	 in	 the	 serum	 of	 AdvSM	 patients	 compared	with	 healthy	 controls	 and	 CM	 patients	
(Mueller	et	al.,	,-./).		
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Neoplastic	 markers.	Other	 markers	 are	 reported	 on	 neoplastic	 progenitor	 cells	 in	 myeloid	
neoplasms,	including	CD22	and	CD342.	Normal	mast	cells	and	basophils	express	low	levels	of	
the	myeloid	marker	CD00	(Siglec-!),	whereas	expression	is	higher	on	SM	mast	cells	(Krauth	et	
al.,	 &''().	 CD%%	 expression	 is	 found	 in	 early	 differentiation	 and	 is	 an	 aberrant	marker	 on	
CD#$+	CD#$−	neoplastic	progenitor	cells	and	basophils	 in	myeloid	neoplasms	(Florian	et	al.,	
!""#).	Normal	stem	and	progenitor	cells,	as	well	as	basophils	and	dendritic	cells	express	the	
IL-!R,	CD%&'.	CD%&'	is	detectable	on	neoplastic	mast	cells	of	all	ASM	patients,	whereas	only	a	
subset	of	the	ISM	and	SM-AHN	patients	have	CD#$%	expression	on	their	mast	cells.	However	
CD#$%	is	not	detected	in	MCL	(Pardanani	et	al.,	./01b).		
Other	 markers.	 The	 pan	 leukocyte	 marker	 CD34,	 also	 expressed	 on	 normal	 mast	 cells	 has	
increased	 expression	on	SM	mast	 cells	 (Chisholm	et	 al.,	 /012).	The	majority	 of	 SM	patients	
have	bright	expression	of	the	complement	receptor	type	I,	CD+,,	on	their	mast	cells,	whereas	
normal	mast	cells	 lack	CD/0	expression.	 (Escribano	et	al.,	 1223b;	 Jabbar	et	al.,	6718).	Other	
complement	receptors	CD..,	CD01	and	CD##c	also	have	higher	expression	on	SM	mast	cells	
(Nunez-Lopez	et	al.,	,--.).	Interestingly,	tumor	cell	marker	PD-L"	is	also	present	in	neoplastic	
mast	cells	in	the	bone	marrow	and	skin	(Rabenhorst	et	al.,	0123)		
Gene	expression.	The	gene	expression	of	neoplastic	mast	cells	from	the	bone	marrow	is	studied	
using	microarrays	(D'Ambrosio	et	al.,	2334;	Teodosio	et	al.,	2384).	As	expected,	high	tryptase	
expression	in	mononuclear	cells	distinguishes	SM	patients	from	healthy	controls	(D'Ambrosio	
et	al.,	())*).	Isolated	bone	marrow	mast	cells	from	ISM	and	ASM	patients	showed	a	common	
expression	profile	with	several	deregulated	transcripts	related	to	the	immune	response,	as	well	
as	KIT	and	tryptase	(Teodosio	et	al.,	./01).	However,	mast	cells	from	ISM	patients	have	some	
specific	upregulated	proteins	that	are	involved	in	signaling	pathways	and	degranulation.	
	
FIGURE	!.	Neoplastic	mast	 cells	 in	SM	express	 several	 aberrant	 surface	makers	 compared	 to	normal	
mast	cells.	CD,-,	CD,,,	CD/0,	CD/1,	and	CD00	are	expressed	on	normal	mast	cells,	but	have	increased	
expression	on	neoplastic	mast	cells.	
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ASM	mast	 cells	have	more	altered	genes	 involved	 in	 apoptosis,	 cell	 cycle,	 proliferation,	 and	
DNA	 repair.	 It	 is	 not	 reported	 whether	 these	 transcripts	 are	 associated	 with	 additional	
mutations	found	in	ASM.		
It	 is	not	clear	why	these	markers	are	elevated	and	what	 they	have	 in	common.	Some	of	 the	
aberrant	markers	are	undetectable	on	normal	mast	cells,	whereas	other	aberrant	markers	are	
present	 at	 low	 levels	 in	 normal	 mast	 cells	 and	 show	 an	 increase	 in	 neoplastic	 mast	 cells.	
Interestingly,	signaling	of	oncogenic	KIT-activated	RAS	and	STAT	induces	expression	of	CD#$	
and	CD''	(Hoermann	et	al.,	./01a;	Mueller	et	al.,	./05).	The	complex	signaling	network	of	
KIT	likely	causes	aberrant	expression	when	KIT	is	mutated,	but	there	is	only	limited	evidence	
for	this.	
1.7.4 KIT	MUTATIONS	
The	 most	 common	 mutation	 in	 SM,	 included	 as	 minor	 criterion	 for	 SM	 diagnosis,	 is	 the	
mutation	in	exon	+,	of	the	KIT	gene	affecting	the	aspartic	acid	(D)	at	amino	acid	position	456.	
In	SM	this	mutation	results	in	the	change	to	valine	(D./0V),	but	there	are	other,	less	common	
changes	at	this	position	including	D123F,	D123H,	D123I,	and	D123Y	(Arock	et	al.,	./01).	The	
D"#$V	 mutation	 leads	 to	 SCF-independent	 activation	 of	 the	 intracellular	 tyrosine	 kinase	
domain	of	KIT,	which	induces	phosphorylation	of	downstream	pathways.	(Furitsu	et	al.,	.//0).	
The	 STAT'-PI#K	 signaling	 pathway	 is	 strongly	 affected	 by	 KIT	D"#$V	 (Harir	 et	 al.,	 ,--.;	
Xiang	et	al.,	,--.).	In	vitro	inhibition	of	STAT,	abrogates	the	growth	of	KIT	D"#$V	expressing	
mast	cells	from	SM	patients	through	direct	activation	of	STAT$	by	KIT	D"#$V	(Baumgartner	et	
al.,	 &''().	 Similarly,	 KIT	 D./0V	 activates	 mTOR	 in	 the	 PI<K/mTOR	 signaling	 pathway.	
Targeting	mTOR	with	rapamycin	 inhibits	proliferation	of	KIT	D"#$V	mast	cell	but	not	mast	
cells	with	wildtype	KIT	 (Gabillot-Carre	et	al.,	)**+).	 In	contrast,	downstream	proteins	 from	
the	MAPK	pathway	are	not	constitutively	active	in	KIT	D"#$V	mutated	cells,	showing	that	not	
all	downstream	pathways	are	affected	by	this	mutation	(Chian	et	al.,	%&&')	(figure	!).	
The	KIT	D"#$V	mutation	 is	 the	most	 common	mutation	 in	 adult	 patients.	The	majority	 of	
these	SM	patients	also	carry	the	KIT	D"#$V	mutation	in	skin	lesions	(Kristensen	et	al.,	./01).	
In	 contrast,	 skin	 lesions	 are	 present	 in	 >!"%	 of	 pediatric	 patients	 but	 only	 !"%	 of	 these	
patients	carry	 the	KIT	D"#$V	mutation	 in	 the	 skin	or	bone	marrow	 (Hartmann	et	al.,	-./0;	
Méni	et	al.,	()*+).	The	most	common	KIT	mutations	in	pediatric	patients	exist	 in	exon	',	),	
and	%%,	located	in	the	extracellular	and	juxtamembrane	domain	of	KIT	(Bodemer	et	al.,	.//0).	
These	mutations	are	not	exclusively	present	in	pediatric	mastocytosis,	but	are	also	reported	in	
patients	with	gastrointestinal	 stromal	 tumors	 (GIST).	KIT	D"#$V	 is	 a	 somatic	mutation	and	
not	inherited,	whereas	other	KIT	mutations	are	found	to	be	germline	mutations,	resulting	in	
familial	cases	of	SM	and	GIST	(Hartmann	et	al.,	-../).		
A	 commonly	 used	 method	 to	 detect	 the	 KIT	 D"#$V	 mutation	 is	 an	 allele-specific	 qPCR	
(Kristensen	 et	 al.,	 ./00).	Calculating	 the	 ratio	 between	KIT	D"#$V	 and	wildtype	KIT	 alleles	
gives	the	percentage	mutated	KIT	alleles	which	provides	an	estimation	of	the	disease	burden.	
The	median	KIT	D"#$V	allele	burden	in	all	SM	patient	is	!.#$%%,	ranging	from	!.!!%-!".$%&%.	
The	KIT	D"#$V	allele	burden	correlates	with	SM	subtype,	with	significant	reduced	probability	
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of	survival	with	an	allele	burden	of	≥!%	 (Hoermann	et	al.,	./01b).	Follow-up	assessment	of	
the	 ISM	 patients	 shows	 a	 stable	 mutation	 burden	 in	 patients	 with	 stable	 clinical	 course,	
whereas	an	increase	in	mutation	burden	 is	present	 in	patients	with	disease	progression.	The	
KIT	 D"#$V	 mutation	 is	 not	 detected	 in	 about	 ,--!"%	 of	 patients	 with	 MCL,	 whereas	
alternative	mutations	at	position	D*+,	are	reported	(Jawhar	et	al.,	&'()).	
The	peripheral	blood	is	another	source	for	detection	of	the	KIT	D"#$V	mutation.	Since	mast	
cells	usually	do	not	 circulate	 in	 the	blood,	 the	detection	of	 the	mutation	 comes	 from	other	
hematopoietic	 cells,	 mature	 cells	 or	 progenitors.	 Indeed,	 several	 studies	 reported	 the	 KIT	
D"#$V	 mutation	 in	 mature	 blood	 cells	 of	 SM	 patients	 other	 than	 mast	 cells,	 showing	
multilineage	 involvement.	 KIT	 D"#$V	 is	 present	 in	 lymphocytes,	 monocytes,	 neutrophils,	
basophils,	and	eosinophils	(Garcia-Montero	et	al.,	,--.;	Kocabas	et	al.,	,--4;	Mayado	et	al.,	
!"#$;	 Pardanani	 et	 al.,	 !""2;	 Yavuz	 et	 al.,	 !""!).	 Furthermore	 colonies	 from	 erythroid	
progenitors	 and	 granulocyte/monocyte	 precursors	 from	 AdvSM	 patients	 carry	 KIT	 D"#$V	
(Afonja	 et	 al.,	 .//0;	 Jawhar	 et	 al.,	 67.8).	 A	 report	 on	 associated	 neoplasms	 detected	 the	
mutation	 in	neoplastic	CD01+	myeloid	 cells	 (Sotlar	 et	 al.,	 ,--.).	As	 expected,	CD#$+	 sorted	
hematopoietic	 progenitors	carry	KIT	D"#$V	 in	patients	with	different	 SM	 subtypes	 (Garcia-
Montero	et	al.,	,--.;	Mayado	et	al.,	,-23).	However,	it	remains	to	be	confirmed	if	KIT	D"#$V	
is	present	in	specific	hematopoietic	stem	and	progenitor	cells.	
Interestingly,	 it	 seems	 that	 the	KIT	D"#$V	mutation	 is	 not	 restricted	 to	 the	 hematopoietic	
system,	 since	mesenchymal	 stromal	cells	 can	carry	 the	mutation	as	well	(Garcia-Montero	et	
al.,	 &'();	 Nemeth	 et	 al.,	 &'(0).	 In	 addition,	 CCL%,	 a	 proangiogenic	 cytokine	 released	 by	
aberrant	mast	cells,	promote	alterations	of	the	tumor	microenvironment,	tested	in	vivo	and	in	
vitro	(Greiner	et	al.,	-./0).	Together	these	findings	suggest	that	aberrant	KIT	signaling	in	mast	
cells	as	well	as	the	stroma	cells	affects	the	bone	marrow	niche.	
Not	much	is	known	about	the	effect	of	KIT	D"#$V	on	other	cells	than	the	mast	cell.	Current	
knowledge	is	based	on	primary	mast	cells	from	patient	samples	and	human	mast	cell	lines	that	
harbor	the	KIT	D"#$V	mutation;	HMC-!.#,	derived	from	a	patient	with	MCL	(Sundstrom	et	al.,	
!""#),	and	ROSA	KIT	D"#$V	cells,	cord	blood	derived	mast	cells	transduced	with	a	KIT	D"#$V	
construct	 (Saleh	 et	 al.,	 +,-.).	 ROSA	KIT	D"#$V	 cells	 injected	 in	 a	mouse	model	 results	 in	
engraftment	of	 the	 cells	 in	 the	bone	marrow,	 spleen,	 liver	 and	peripheral	blood	 (Bibi	 et	 al.,	
!"#$).	This	model	provides	an	interesting	tool	to	study	the	effect	of	potential	drugs,	but	will	
not	 provide	 more	 insight	 into	 disease	 etiology	 or	 pathogenesis.	 Other	 transgenic	 animal	
models	in	mice	and	zebra	fish	enables	studies	on	KIT	D"#$V	in	development	(Balci	et	al.,	,-./;	
Gerbaulet	 et	 al.,	 ,-..;	Weidemann	et	 al.,	 ,-.5;	Zappulla	et	 al.,	 ,--8).	 In	mice,	 inducing	 the	
murine	homologue	of	KIT	D"#$V,	Kit	D"#$V,	in	germline	cells	results	in	perinatal	lethality	due	
to	hyperproliferation	of	the	erythroid	lineage.	Introducing	the	mutation	after	birth	gives	mast	
cell	 infiltrates	 in	 the	 skin,	 lymph	 nodes,	 spleen,	 forestomach,	 intestinal	 mucosa	 and	 liver	
(Gerbaulet	 et	 al.,	 -.//).	These	 findings	might	 not	 be	 directly	 translatable	 to	 humans,	 but	 it	
might	explain	why	the	KIT	D"#$V	is	a	somatic	mutation	and	not	inherited.	
Whereas	mastocytosis	is	not	reported	to	occur	naturally	in	mice,	mast	cell	tumors	present	the	
most	common	skin	tumors	in	dogs.	Similar	to	human	mast	cell	sarcoma,	sequencing	data	of	
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the	 kinase	 domain	 of	 canine	KIT	does	not	 present	 any	mutations	 in	 this	 domain,	 whereas	
activating	 mutations	 are	 found	 in	 other	 exons	 of	KIT	 (Letard	 et	 al.,	 ,--.;	Webster	 et	 al.,	
!""#).	
1.7.5 ASSOCIATED	MUTATIONS		
In	addition	to	KIT	D"#$V,	patients	with	SM	can	carry	associated	mutations,	most	commonly	
present	in	SM-AHN	followed	by	ASM	and	only	rarely	in	ISM	(Pardanani	et	al.,	./01a;	Schwaab	
et	al.,	()*+).	The	presence	of	additional	mutations	is	associated	with	a	significantly	reduction	
in	overall	 survival	 (Schwaab	et	 al.,	 ./01).	Most	of	 the	associated	mutations	are	known	 from	
other	myeloid	neoplasms	(Mian	et	al.,	,-./).	However,	patients	with	myeloid	neoplasms	can	
also	carry	the	KIT	D"#$V	mutation,	as	shown	in	patients	with	CMML	or	AML,	presenting	an	
associated	 SM	 in	CMML,	 but	 not	 in	AML	 (Jawhar	 et	 al.,	 -./0;	Kristensen	 et	 al.,	 -./-).	The	
most	 common	 associated	 mutations	 in	 SM	 are	 TET#,	 SRSF&,	 ASXL*,	 RUNX*,	 N/KRAS	 and	
JAK$,	involved	in	epigenetic	regulation,	RNA	splicing	or	cell	signaling	pathways	(Hanssens	et	
al.,	 &'();	 Jawhar	 et	 al.,	 &'(1).	 The	 combination	 of	mutations	 in	 SRSF$,	ASXL%,	RUNX%	 and	
EZH$	adversely	correlates	with	overall	survival	(Jawhar	et	al.,	-./0).	The	combination	of	TET#	
mutations	with	KIT	D"#$V	presents	a	more	aggressive	phenotype	compared	with	KIT	D"#$V	
only	 (De	 Vita	 et	 al.,	 ,-./;	 Soucie	 et	 al.,	 ,-.,).	 TET#	 has	 a	 regulatory	 role	 in	 mast	 cell	
differentiation	and	function	(Montagner	et	al.,	./01).	Interestingly,	analysis	of	colonies	grown	
in	 myeloid	 restricted	medium	 from	 sorted	 CD./+	 progenitors	 suggest	 that	 the	 associated	
mutations	TET#,	SFSF#	and	ASXL%	are	acquired	before	the	KIT	D"#$V	mutation	(Jawhar	et	al.,	
!"#$).	 It	 is	 unknown	 if	 KIT	 D"#$V	 and	 associated	 mutations	 arise	 from	 a	 single	 clone	 or	
whether	they	arise	separately.	In	addition,	the	presence	of	a	neoplastic	stem	cell	is	shown	in	
other	myeloid	neoplasms,	making	 them	 stem	 cell	 diseases.	A	 similar	 neoplastic	 stem	 cell	 is	
described	 in	 MCL	 patients,	 but	 is	 thus	 far	 not	 reported	 in	 other	 subtypes	 of	 SM	 patients	
(Eisenwort	et	al.,	0123;	Valent	et	al.,	0126).	
1.8 MAST	CELLS	AS	TARGETS	OF	TREATMENT	
There	 is	 currently	 no	 curative	 treatment	 option	 for	 SM.	 Patients	 are	 mainly	 receiving	
medication	 that	 targets	mast	 cell	mediators,	 such	as	 anti-histamines,	 leukotriene	 inhibitors,	
anti-interferon	and	steroids.	In	the	recent	years,	new	treatment	concepts	have	been	developed	
and	tested.	However,	since	SM	is	heterogeneous,	there	is	not	one	best	treatment	option	and	
therefore	 the	 field	 is	 moving	 more	 towards	 personalized	 medicine.	 Some	 of	 the	 recently	
developed	treatments	that	show	promising	results	are	discussed	below.	
Tyrosine	kinase	inhibitors	(TKI).	Since	the	main	mutation	in	SM	is	located	in	the	KIT	receptor,	
it	makes	sense	to	target	the	receptor	directly,	thereby	blocking	all	downstream	signaling.	The	
TKI	 imatinib,	 initially	designed	 for	 treatment	of	CML	 to	 target	 the	BCR-ABL	fusion	protein,	
targets	 the	 KIT	 receptor	 (Druker	 et	 al.,	 -../).	 Mechanistic	 studies	 showed	 that	 imatinib	
inhibits	mast	 cell	 lines	with	 the	V./0G	mutation,	 but	not	with	 the	D78/V	mutation	 and	 is	
therefore	not	used	for	SM	patients	(Ma	et	al.,	*++*).	The	conformational	change	in	the	kinase	
domain	of	KIT	caused	by	the	D123V	mutation	makes	the	binding	site	for	imatinib	inaccessible	
(Laine	et	al.,	,-..).	However,	imatinib	gives	a	good	response	in	SM	patient	without	mutations	
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in	exon	'(	of	the	KIT	receptor	(Alvarez-Twose	et	al.,	,-./).	New	TKI’s	are	under	development	
since.	Multi-TKI,	midostaurin	(PKC!"#),	inhibits	wildtype	KIT	as	well	as	KIT	D"#$V	(Gleixner	
et	al.,	())*).	Midostaurin	 is	evaluated	 in	clinical	 trials	and	 is	recently	approved	by	the	FDA	
and	EMA	for	treatment	of	ASM	(Gotlib	et	al.,	-./0;	Kasamon	et	al.,	-./6).	Another	promising	
TKI	 is	currently	 tested	 for	safety	 in	a	phase	II	clinical	 trial	 for	 treatment	of	 ISM	and	ASM	 is	
avapritinib	(BLU-!"#;	NCT$%&%'()$	and	NCT$%!"#$%&)	(Lubke	et	al.,	-./0).		
Downstream	 signaling	 pathways.	 Small	 molecular	 inhibitors	 can	 target	 activated	 signaling	
downstream	of	KIT.	The	JAK/STAT	signaling	pathway	provides	an	interesting	target	since	KIT	
D"#$V	directly	activates	it	(Baumgartner	et	al.,	/001).	JAK	inhibitor	ruxolitinib	is	tested	in	SM	
patients	 and	 improved	 the	 quality	 of	 life,	 though	 does	 not	 affect	 mast	 cells	 infiltration	 or	
tryptase	 levels	 (Dowse	 et	 al.,	 -./0;	 Yacoub	 and	 Prochaska,	 -./<).	 However,	 multi-kinase	
inhibitor	R*+,	shows	promising	effects	by	growth	inhibition	of	neoplastic	mast	cells	through	
inhibiting	 STAT$	 phosphorylation	 (Peter	 et	 al.,	 +,-.).	 Targeting	 the	 PI#K/mTOR	 is	 less	
effective.	Targeting	mTOR	is	promising	in	human	cell-lines,	however	the	oral	mTOR	inhibitor	
everolimus	does	not	give	clinical	improvement	in	patients	(Gabillot-Carre	et	al.,	*++,;	Parikh	
et	al.,	()*)).		
Surface	proteins.	As	mentioned	previously,	neoplastic	mast	cells	in	SM	express	several	aberrant	
proteins,	 making	 them	 possible	 targets.	 So	 far	 only	 a	 few	 surface	 proteins	 are	 used	 in	 the	
development	of	targeted	therapies.	The	monoclonal	antibody	brentuximab	vedotin	targeting	
CD#$	is	tested	in	a	few	patients,	showing	a	reduction	of	disease	burden	in	+/-	patients	(Borate	
et	al.,	()*+).	The	low	toxicity	of	this	drug	is	promising	and	the	efficacy	is	further	investigated	
in	a	phase	II	clinical	trial	(NCT$%&$'()&).	The	antibody	alemtuzumab	targeting	CD+,	induces	
favorable	 effects	 in	 cell	 lines	 and	 mice,	 but	 is	 not	 evaluated	 in	 clinical	 studies	 so	 far	
(Hoermann	et	al.,	./01a).	Gemtuzumab	ozogamicin	targets	CD44	with	a	monoclonal	antibody	
conjugated	to	a	cytostatic	agent,	commonly	used	for	CD11+	AML	and	successful	in	treatment	
of	a	MCL	patient	with	no	response	to	other	therapies	(Krauth	et	al.,	-../).	Aberrant	CD,-.	
expression	 on	 neoplastic	 mast	 cells	 provides	 another	 promising	 target	 for	 monoclonal	
antibodies,	 of	 which	 SL-!"#	 is	 currently	 tested	 in	 clinical	 trials	 for	 efficacy	 and	 safety	 for	
treatment	of	advanced	myeloproliferative	neoplasms	 including	SM	(NCT$%%&'%())	(Frankel	
et	al.,	()*+;	Pardanani	et	al.,	()*2b)	
Epigenetics.	Research	 into	epigenetics	 is	 increasing	 in	 the	research	areas	of	different	kind	of	
malignancies.	Histone	deacetylase	inhibitor	vorinostat	(SAHA)	selectively	induces	apoptosis	in	
KIT	D"#$V	mutated	cells	in	vitro	as	well	as	ex	vivo	using	primary	neoplastic	mast	cells	(Lyberg	
et	al.,	()*+)	
Allogeneic	hematopoietic	cell	transplantation.	Currently	the	only	method	available	to	remove	
mutated	 progenitor	 cells	 for	 advanced	 hematological	 diseases	 is	 through	 the	 complete	
replacement	 of	 all	 hematopoietic	 stem	 progenitor	 cells	 by	 allogeneic	 hematopoietic	 cell	
transplantation	 from	 a	 genetically	 similar	 donor.	 From	 3445	 several	 patients	 with	 AdvSM	
receiving	 an	 allogeneic	 transplant	 published	 in	 several	 case	 studies	 (Ustun	 et	 al.,	 -./0).	
Clinical	outcome	depends	on	the	SM	subtype	but	./%	of	the	subjects	are	progression-free	after	
!	 years.	 Responding	 patients	 have	 significant	 lower	 percentages	 of	 mast	 cells	 in	 the	 bone	
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marrow	 as	 well	 as	 lower	 serum	 tryptase	 levels.	 Thus,	 allogeneic	 transplantation	 provides	 a	
possible	 treatment	option	 for	patients	with	 advanced	SM.	However,	 it	 has	 to	be	noted	 that	
most	 of	 the	 SM	 patients	 are	 not	 eligible	 for	 stem	 cell	 transplantation	 due	 to	 age	 and	 or	
comorbidities.	
  19 
2 AIMS	
The	overall	aim	of	this	thesis	is	to	gain	more	insights	into	mast	cell	development	in	health	and	
to	 compare	 it	 to	 systemic	mastocytosis	 thereby	 increasing	basic	 understanding	 and	 identify	
novel	targets	for	potential	therapies	in	systemic	mastocytosis.	
	
The	specific	aims	were:	
	
Study	I	 To	investigate	the	presence	of	mast	cells	in	the	blood	of	systemic	
	 mastocytosis	patients	
	
Study	II	 To	study	the	role	of	SCF	and	KIT-signaling	in	mast	cell	development	
	
Study	III	 To	identify	the	origin	of	the	KIT	D!"#V	mutation	within	hematopoietic	stem	
and	progenitor	cells	of	systemic	mastocytosis		
	
Study	IV	 To	identify	a	mast	cell-basophil	bone	marrow	progenitor			
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3 METHODOLOGICAL	APPROACHES	
This	chapter	briefly	describes	the	main	methods	and	materials	used	in	this	thesis.	More	details	
are	provided	in	the	materials	and	methods	section	of	each	study.	
3.1 ETHICAL	CONSIDERATIONS	
The	Ethical	committees	of	Stockholm	and	Uppsala	provided	permission	for	the	use	of	human	
bone	marrow	 and	 peripheral	 blood	 samples.	 Sample	 collection	was	 in	 accordance	with	 the	
World	Medical	Association	Declaration	 of	Helsinki.	 Before	 donation,	 patients	 provided	oral	
and	written	consent	to	qualified	clinicians	involved	in	the	studies.	
3.2 HUMAN	SAMPLES	
We	collected	peripheral	blood	samples	from	patients	diagnosed	with	systemic	mastocytosis	in	
study	 I	 and	 II,	and	 from	patients	with	 chronic	myeloid	 leukemia	 (CML)	 or	 gastrointestinal	
stromal	tumors	(GIST),	of	which	some	were	treated	with	imatinib	in	study	II.	Patient	samples	
were	compared	with	anonymous	healthy	controls	from	buffy	coats	or	donations	at	the	blood	
bank.	
For	 study	 III	and	 IV	we	collected	bone	marrow	samples	 from	patients	under	evaluation	 for	
mastocytosis.	 Control	 samples	 in	 study	 III	 included	 bone	marrow	 from	healthy	 volunteers,	
and	 patients	 that	 were	 suspected	 of	 mastocytosis	 but	 did	 not	 fulfill	 the	 criteria	 for	 the	
diagnosis.	 Three	 of	 the	 control	 subjects	 had	 urticaria	 pigmentosa	 and	 where	 therefore	
classified	with	CM.	Study	III	included	)*	patients	and	/	control	subjects.	Study	IV	includes	!"	
bone	 marrow	 samples,	 of	 which	 five	 from	 patients	 diagnosed	 with	 different	 mastocytosis	
subtypes	and	five	from	healthy	volunteers.	
3.3 SAMPLE	PROCESSING	
Cells	from	bone	marrow	and	peripheral	blood	were	isolated	using	a	standardized	method	for	
cell	 isolation	based	on	 lysis	 of	 erythrocytes	by	 ammonium	chloride	potassium	 (ACK)	buffer	
(study	 I),	 or	 PharmLyse	 (BD	Biosciences)	 (study	 I-IV).	 In	 study	 II,	mononuclear	 cells	were	
isolated	from	buffy	coats	using	Ficoll-Paque	PLUS	(GE	Healthcare).	For	erythrocyte	lysis	using	
ACK	buffer,	we	added	./	mL	of	ACK	buffer	to	.	mL	of	whole	blood	and	incubated	for	9	min.,	
followed	by	several	washing	steps	using	FACS	buffer	(PBS	with	<%	heat-inactivated	Fetal	Calf	
Serum).	For	lysis	with	PharmLyse,	we	added	7.8	volumes	of	7x	PharmLyse	to	the	sample	and	
incubated	 for	 !	 min,	 after	 which	 several	 washing	 steps	 with	 PBS	 and	 FACS	 buffer	 further	
cleaned	the	sample.		
3.4 FLOW	CYTOMETRY	
We	used	 several	multi-color	 flow	 cytometry	 panels	 for	 sample	 analysis	 (study	 I-IV).	 Panels	
were	designed	based	on	published	studies	in	which	they	confirmed	the	gating	strategy	of	the	
cell	by	culture	experiments.	A	combination	of	lineage	markers	excluded	lymphocytes	and/or	
monocytes:	 CD-.,	 CD0,	 CD-1,	 CD.,	 and/or	 CD6.	 Since	 SM	 mast	 cells	 can	 express	 several	
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aberrant	markers	(Teodosio	et	al.,	./01),	when	gating	mast	cells,	only	CD34,	or	a	combination	
of	CD&',	CD),	and	CD&-	was	used	to	exclude	lineage	cells	in	study	I-III,	and	IV	respectively.	
Fluorescent	minus	one	(FMO)	controls	were	used	to	confirm	the	antibody	staining	and	to	set	
the	gates	when	analyzing	or	sorting	the	samples.	The	preferred	method	for	gating	in	all	studies	
was	 the	use	an	 internal/biological	control.	For	example,	 in	 study	 III	CD#$+	cells	were	gated	
using	CD'(−	CD#$+	HSCs	from	the	same	sample.	
3.5 FLUORESCENT-ACTIVATED	CELL	SORTING	
Cells	were	sorted	for	different	downstream	assays	using	the	FACS	ARIA	I	or	ARIA	Fusion	(BD	
Biosciences).	When	sorting	rare	population	from	bone	marrow	or	blood,	we	used	a	two-step	
sorting	 protocol.	 The	 first	 sorting	 round	 we	 used	 the	 ‘yield’	 precision	mask,	 followed	 by	 a	
‘purity’	precision	mask	at	the	second	round.	Sorted	cells	were	checked	for	purity	by	recording	
!"-!""	 cells	 that	 were	 sorted	 in	 sterile	 filtered	 FACS	 buffer	 after	 thorough	 cleaning	 of	 the	
machine.	Purity	was	usually	>!"%.		
For	single	cell	sorting	(study	III)	we	followed	a	one-step	sorting	protocol	using	the	single-cell	
precision	mask	at	a	low	flow	rate	combined	with	the	index-sorting	option.	The	index-sorting	
option	saves	 the	 flow	cytometry	 standard	 (fcs)	data	 for	 each	 sorted	 single	 cell	 linked	 to	 the	
specific	well.	Between	./-!"	single	cells	were	sorted	into	a	1"-well	plate,	leaving	several	wells	
as	control	wells	 in	every	plate.	Controls	 included	single	mast	cells	 from	the	same	sample,	at	
least	'	empty	wells,	and	at	least	/	wells	with	a	population	of	5-!"	cells.	Since	only	one	cell	was	
sorted	per	well	 directly	 into	 lysis	 buffer,	 purity	 cannot	 be	 assessed,	 however,	 the	 single-cell	
sort	precision	sets	very	specific	restrictions	on	when	to	sort	a	cell.	
3.6 CELL	CULTURES	
In	vitro	cell	cultures	in	study	II,	III,	and	IV	measured	cell	potential	of	sorted	progenitors.	For	
mast	cell	potential,	cultures	were	supplemented	with	a	combination	of	IL-!	($%	ng/mL),	IL-!	
("#	 ng/mL),	 and	 SCF	 (&''	 ng/mL).	 However,	 the	 high	 concentration	 of	 SCF	 resulted	 in	
internalization	of	CD../,	which	makes	 flow	 cytometry	 analysis	 of	 the	 receptor	uncertain.	 In	
order	to	allow	for	flow	cytometry	analysis,	we	reduced	the	concentration	of	SCF	to	0	ng/mL	in	
study	 IV.	 Addition	 of	 EPO	 (!	 IU/mL),	 and	 GM-CSF	 (!"	 ng/mL)	 allowed	 for	 erythroid	 and	
monocyte-granulocyte	differentiation	of	sorted	progenitors.	
In	 study	 III,	 we	 used	 colony-forming	 assays	 in	 semi-solid	 medium	 to	 confirm	 the	 gating	
strategy	of	previously	described	progenitors,	the	CMPs,	GMPs,	and	MEPs.	
3.7 CELL	CULTURE	ANALYSIS	
We	 analysed	 the	 potential	 of	 cultured	 cells	 by	 flow	 cytometry	 (study	 II-IV)	 and	 histology	
staining	 using	May-Grünwald	Giemsa	 (MGG)	 (study	 I-IV).	 Enzymatic	 staining	 using	 Z-Gly-
Pro-Arg-!-methoxy-β-naphthylamide	 and	 Fast	 Garnet	 GBC	 visualized	 tryptase-expressing	
cells	(Harvima	et	al.,	 ./00).	For	photos	at	magnification	122x,	the	slides	were	mounted	with	
different	mounting	solutions.	MGG	stained	slides	with	Pertex	(Histolab)	and	tryptase-stained	
slides	with	SlowFade	Gold	Antifade	mountant	(Thermofisher)	
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Flow	 cytometry	 antibody	 panels	 identified	 mature	 immune	 cells	 including	 mast	 cells,	
basophils,	 monocytes	 and	 neutrophils,	 and	 erythrocytes.	 Staining	 with	 DAPI	 or	 !-AAD	
enabled	exclusion	of	dead	cells	in	the	cultures.	
3.8 KIT	D816V	MUTATION	ASSAY		
Study	I	and	III	utilize	a	mutation	assay	that	was	adapted	from	the	standardized	method	in	the	
clinic	to	analyze	patient	bone	marrow	and	blood	for	the	KIT	D"#$V	mutation	(Kristensen	et	
al.,	&'(().	In	study	I,	we	isolated	extracted	DNA,	performed	a	pre-amplification	and	performed	
the	qPCR	on	the	cleaned	PCR	product	using	the	original	primers	and	protocol	described	by	
Kristensen	et	al	(!"##).		
The	 method	 was	 further	 optimized	 for	 single	 cell	 analysis	 in	 study	 III.	 The	 method	 was	
optimized	in	several	steps:	
• Primer	 design:	 the	 primers	 that	 are	 specific	 for	 the	KIT	 D"#$V	 mutation	 described	 by	
Kristensen	et	al.	(-.//)	are	designed	with	a	mismatch	at	the	/’-minus	'	position.	We	found	
that	using	a	KIT	D"#$V	primer	without	mismatch	was	more	specific	when	using	low	cell	
numbers	(figure	!).	
• Multiplexing:	 every	 sorted	 cell	 needed	 a	 control	 assay	 to	 validate	 the	 mutation	 assay.	
Using	a	multiplex	qPCR	assay	allowed	us	to	remove	a	preamplification	step	and	made	the	
assay	less	labor	intense.	We	designed	a	control	assay	in	the	stable	gene	GAPDH,	which	is	
not	 likely	 to	get	mutated	 in	disease	 situations.	The	designed	primers	 amplified	a	 region	
flanking	exon	,	and	intron	,,	which	allowed	to	detect	DNA	from	/	cell	and	distinguish	!	
cell	from	multiple	cells.	
• Testing	in	cells:	we	used	two	mast	cell-lines	for	testing,	ROSA	cells	that	have	wildtype	KIT,	
and	 HMC-!.#	 that	 carry	 the	 KIT	 D"#$V	mutation.	 We	 used	 purified	 DNA	 for	 quality	
control	of	the	primers	and	sorted	1,	3,	 14,	and	144	cells	 for	testing	the	combined	sorting	
and	mutation	analysis	by	qPCR.		
	
	
FIGURE	!.	Binding	of	the	reverse	primer	of	the	mutation	assay	to	wildtype	and	mutated	KIT	at	position	
D!"#	
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• Cell	lysis:	to	reduce	the	pipetting	steps	and	risk	of	contamination,	we	aimed	to	sort	cells	
directly	 into	 lysis	 buffer.	 The	 lysis	 buffer	 contained	 Qiagen’s	 elution	 buffer	 (EB)	
supplemented	with	./mM	Tris-Cl	(pH	'.))	with	/0	mg/mL	Proteinase-K	(Thermo	Fisher	
Scientific)	for	!"	min.	at	!!	°C	followed	by	heat-inactivation	of	the	proteinase	for	!"	min.	
at	!"	°C.	
• Single	cell	index	sorting:	we	labeled	the	ROSA	and	HMC-!.#	cells	with	different	antibodies	
for	CD''(,	mixed	 them	 in	 a	 ':'	 ratio	 and	 sorted	 single	 cells	 into	-.-well	 plates	 gated	on	
singlets.	After	sorting,	cells	were	lysed	and	subjected	to	the	multiplex	assay.	We	saved	the	
data	 for	 each	 well	 using	 the	 index-sorting	 option	 in	 the	 software,	 allowing	 for	 a	 blind	
testing	of	the	assay	(figure	!).	
SM	patient	samples	were	used	for	single	cell	sorting	when	there	was	a	clear	indication	that	the	
patient	carried	the	KIT	D"#$V	mutation.	For	each	patient	we	aimed	to	sort	between	#9-!"	$%-
well	plates	to	get	about	-...	cells	to	for	KIT	D"#$V	qPCR	analysis.		
	
	
FIGURE	 !.	 Amplification	 of	 the	 control	 and	 KIT	 D"#$V	 mutation	 assay	 in	 single	 cells	 and	 cell	
populations	from	cell-lines	(A)	and	single	bone	marrow	cells	(B).	
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4 RESULTS	AND	DISCUSSION	
This	 chapter	 gives	 an	 overview	 of	 the	 main	 findings	 of	 each	 study	 and	 discusses	 their	
relevance.	The	figures	and	tables	referred	to	in	the	text	are	found	in	the	corresponding	study	
attached	to	this	thesis.	
4.1 CIRCULATING	MAST	CELLS	IN	ADVANCED	MASTOCYTOSIS	(STUDY	I)	
MCPs,	 CD()+	CD##$hi	 FcεRI+	 cells,	 circulate	 through	 the	 blood	 and	mature,	 CD56−	CD##$hi	
FcεRIhi	cells,	in	the	tissue.	In	SM,	mast	cells	can	infiltrate	and	accumulate	in	different	organs,	
primarily	 detected	 in	 the	bone	marrow.	One	 subtype	of	 SM	 is	MCL,	 in	which	mature	mast	
cells	also	circulate	in	the	peripheral	blood.	However,	it	is	unknown	if	other	subtypes	of	SM	can	
have	circulating	mast	cells.	With	this	 in	mind	we	analyzed	peripheral	blood	samples	 for	the	
presence	of	mast	cell	infiltrates.	
Using	a	multi-color	flow	cytometry	panel,	we	detected	circulating	CD23−	CD##$hi	FcεRIhi	mast	
cells	in	four	patients	that	were	diagnosed	with	SM-AHN	or	ASM	(Figure	(A	and	(B	in	study	I).	
We	did	not	detect	a	population	of	circulating	mast	cells	in	ISM	or	healthy	control	subjects.	We	
detected	the	KIT	D"#!V	mutation	 in	bulk-sorted	mast	cells	carried.	Clinical	analysis	showed	
that	 not	 all	 circulating	 mast	 cells	 in	 the	 four	 patients	 had	 atypical	 morphology	 or	 CD6	
expression,	 and	 serum	 tryptase	 levels	 did	 not	 predict	 the	 presence	 of	 circulating	mast	 cells	
(Table	'	in	study	I).	Thus,	clinical	findings	other	than	SM	subtype,	did	not	correlate	with	the	
presence	of	circulating	mast	cells,	however,	the	size	of	this	patient	cohort	is	too	small	to	draw	
any	conclusion	about	this.	One	possible	explanation	for	the	presence	of	circulating	mast	cells	
in	AdvSM	patients	 is	 that	mast	cells	 leak	 from	highly	 infiltrated	 tissues	 since	 those	patients	
usually	have	a	higher	BMMC	infiltration	rate	compared	to	ISM	patients.	It	is	also	possible	that	
circulating	MCPs	that	carry	the	KIT	D"#$V	mutation	mature	in	the	blood	and	do	not	migrate	
into	tissues.	
Recently,	 after	 we	 published	 this	 study,	 circulating	 mast	 cells	 were	 reported	 in	 a	 few	 ISM	
patients	 and	 control	 subject	 (<!.!!#%	 of	 the	 peripheral	 blood),	 which	 was	 correlated	 to	
BMMC	load	and	serum	tryptase	(Mayado	et	al.,	-./0).	In	our	study	we	did	not	detect	a	distinct	
population	of	circulating	mast	cells	in	ISM	patients.	We	detected	a	few	CD+,−	CD##$hi	FcεRI+	
events	(of	the	total	-.!	events	recorded)	in	ISM	patients	and	control	subjects,	however	this	was	
by	our	definition	not	enough	to	present	a	mast	cell	population.		
As	mentioned,	circulating	mast	cells	are	found	in	MCL,	in	which	the	atypical	form	has	<	;<%	
circulating	mast	cells	from	total	white	blood	cells.	So	how	do	we	distinguish	between	MCL	and	
ASM	and	SM-AHN	in	these	cases	based	on	peripheral	blood?	In	this	study,	the	percentage	of	
mast	cells	in	bone	marrow	smears	was	≤	0.2%	for	all	patients,	which	in	MCL	is	>	<0%	(Table	'	
in	study	I).		
Taken	 together,	 in	 this	 study	 we	 demonstrated	 circulating	 mast	 cells	 in	 patients	 with	
advanced	SM	subtypes.	This	finding	will	not	be	sufficient	to	diagnose	patients	and	requires	a	
study	 in	 a	 larger	 cohort	 of	 patients.	 However	 detecting	mast	 cells	 in	 the	 blood	 using	 flow	
cytometry	presents	a	useful	method	to	monitor	disease	progression.		
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4.2 THE	ROLE	OF	KIT	IN	MAST	CELL	PROGENITOR	DIFFERENTIATION	(STUDY	II)	
In	the	second	study	of	this	thesis,	we	continued	to	study	peripheral	blood,	but	with	the	focus	
on	mast	cell	progenitors.	It	is	commonly	recognized	that	SCF	and	KIT	signaling	are	required	
for	 the	 maturation	 of	 mast	 cells	 and	 is	 included	 into	 almost	 all	 in	 vitro	 differentiation	
protocols.	 In	 this	 study	 we	 aimed	 to	 assess	 the	 role	 of	 SCF	 and	 KIT	 signaling	 in	 the	
differentiation	of	mast	cell	progenitors.	We	analysed	peripheral	blood	from	patients	with	SM,	
CML	 or	 GIST,	 and	 studied	MCP	 differentiation	 by	 culturing	 CD<=+	 selected	 cells	 or	 sorted	
MCPs	from	of	healthy	controls.	
Similar	to	our	findings	in	study	I,	we	detected	circulating	mast	cells	in	a	subset	of	SM	patients,	
but	 interestingly	 we	 also	 detected	 circulating	mast	 cells	 in	 newly	 diagnosed	 and	 untreated	
CML	patients.	These	cells	were	not	present	in	patients	that	were	under	treated	with	imatinib,	
a	drug	that	disrupts	KIT	signaling.	In	contrast,	we	found	that	the	percentage	of	blood	MCPs	is	
unaffected	comparing	several	patients	groups	despite	imatinib	treatment	(Figure	(	in	study	II),	
indicating	that	a	functional	KIT	might	not	be	necessary	for	MCP	development.	
Culture	 experiments	of	CD12+	 selected	 cells	 from	blood	with	addition	of	 IL-!	 and	 IL-!,	but	
without	 addition	 of	 SCF	 gave	 rise	 to	 pre-mast	 cells,	 demonstrating	 that	MCPs	 can	 survive	
without	 KIT	 signaling	 (Figure	 (	 in	 study	 II).	We	 showed	 that	 IL-!	 alone	was	 sufficient	 for	
MCPs	survival,	and	found	that	MCPs	expressed	CD345	(Figure	(	in	study	II).		
Disruption	 of	 the	KIT	 signaling	 by	 addition	 of	 imatinib	 or	 anti-SCF	 to	 the	 cultures	 did	 not	
affect	MCP	survival	(Figure	(	and	,	in	study	II).	Cultures	with	IL-!	and	IL-!	also	showed	some	
maturation	 of	 MCPs,	 measured	 by	 decreased	 CD34	 and	 Integrin	 β"	 expression,	 and	 the	
presence	 of	 tryptase	 expressing	 granules	 (Figure	 (	 in	 study	 II).	 However,	 when	 IL-!	 was	
replaced	after	+	days	by	SCF	for	an	additional	+-!	days,	the	cells	rapidly	matured.	Thus,	SCF	is	
dispensable	for	MCP	survival	and	initial	maturation,	but	is	required	for	definitive	maturation	
of	mast	cells.	
Imatinib	 treatment	 efficiently	depleted	 the	CD''(	expressing	 cells	 in	 the	CML	patients.	 It	 is	
known	 that	 imatinib	 is	 not	 effective	 for	 treatment	 of	 SM	 patients	 with	 the	 KIT	 D"#$V	
mutation	because	imatinib	cannot	target	this	mutation.	This	shows	that	mast	cells	in	CML	do	
not	carry	KIT	D"#$V.	It	is	clear	on	the	flow	cytometry	plot	that	the	population	of	circulating	
mast	 cells	had	 varying	 CD++,	 expression	without	 clear	 separation	 from	 FcεRI+	CD##$−	 cells.	
CML	is	known	for	the	presence	of	basophilia,	in	which	there	are	≥	34%	basophils	in	the	blood	
(Arber	et	al.,	,-./).	These	basophils	are	often	immature	and	express	some	CD##$	(Valent	et	al.,	
!"#$).	One	study	showed	that	immature	CML	basophils	express	and	release	tryptase	(Sperr	et	
al.,	 &'()).	 Currently	 basophils	 and	 mast	 cells	 are	 distinguished	 based	 on	 surface	 CD667	
expression	 and	 intracellular	 tryptase.	 Since	 tryptase	 is	 mainly	 a	 mast	 cell	 marker	 and	 we	
detected	circulating	mast	cells	in	CML	patients,	it	raises	questions	on	the	actual	identity	of	the	
CD""#-expressing	 basophils	 described	 in	 CML.	 It	 is	 interesting	 to	 speculate	 that	 there	 is	 a	
disturbed	differentiation	of	 a	 shared	precursor	of	mast	 cells	 and	basophils	 in	 these	patients	
resulting	in	the	FcεRI+	CD##$+	cells,	however	this	needs	to	be	further	investigated.	
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Based	 on	 the	 differentiation	 experiments	 we	 designed	 a	 new	 culture	 protocol	 to	 study	 the	
mast	cell	potential,	using	only	IL-!	and	IL-!	for	the	first	+	days	in	the	culture.	In	this	way	we	
promote	mast	 cell	 progenitor	 survival	 and	differentiation	without	 creating	bias	 towards	 the	
mast	cell	lineage.	However,	SCF	will	is	required	for	complete	maturation	of	pre-mast	cells.	
4.3 KIT	D816V	IN	SINGLE	CELLS	(STUDY	III)	
The	KIT	D"#$V	mutation	 is	present	 in	different	 lineages	and	detected	 in	bulk	sorted	CD:;+	
progenitors.	 	In	this	study	we	aimed	to	identify	the	origin	of	the	KIT	D"#$V	mutation	in	the	
hematopoietic	 landscape,	 using	 bone	 marrow	 samples	 from	 patients	 under	 evaluation	 for	
systemic	mastocytosis.		
For	 this	 study	we	 designed	 a	multi-color	 flow	 cytometry	 panel	 that	 could	 identify	 different	
progenitor	 populations	 as	 well	 as	 mature	mast	 cells	 (Figure	 (	 in	 study	 III).	 Analysis	 of	 the	
percentage	of	CD./+	HSPCs	did	not	give	a	skewed	hematopoiesis	in	SM,	commonly	observed	
in	myeloid	neoplasms,	and	shown	in	the	hematopoietic	profile	for	the	two	MDS/MPN	patients	
included	in	this	study.	There	was	no	difference	in	the	total	percentage	of	CD89+	cells	for	any	
SM	 subtype	 (Supplementary	 figure	 0	 in	 study	 III).	 We	 observed	 a	 trend	 towards	 a	 lower	
percentage	 of	 lymphoid	 progenitors,	 the	 BNKP,	 in	 patients	 compared	 to	 no	 SM	 controls,	
which	is	expected	since	the	production	of	lymphoid	cells	declines	with	increasing	age	and	the	
control	subjects	were	slightly	younger.	In	addition,	colony	forming	potential	of	CMPs,	GMPs	
and	MEPs	was	similar	in	SM	and	no	SM	subjects.	
Detailed	 analysis	 of	 the	 flow	 cytometry	 data	 of	 all	 patients	 revealed	 aberrant	
immunophenotype	 of	 CD&'RA	 on	 mast	 cells	 of	 SM	 patients	 only	 (Figure	 (	 in	 study	 III).	
Interestingly,	 one	 control	 subject	was	 diagnosed	with	 CM	 and	 had	 slightly	 higher	 CD12RA	
expression.	 It	 will	 be	 interesting	 to	 follow	 this	 patient	 and	 assess	 whether	 this	 patients	
progresses	into	SM.	One	SM	patient	had	lower	CD67RA	expression,	which	can	be	explained	by	
the	diagnosis.	The	biopsy	at	the	time	of	the	aspirate	did	not	show	atypical	morphology	of	mast	
cells,	thereby	not	giving	three	minor	criteria	to	be	diagnosed	with	SM.	However,	a	consecutive	
biopsy	 showed	 atypical	 morphology,	 giving	 the	 diagnosis	 of	 ISM.	 Aberrant	 CD()RA	
expression	 in	SM	has	not	been	described	before	 and	 there	 are	no	 reported	explanations	 for	
aberrant	CD*+RA	expression.	However,	CD*+RA	expression	is	associated	with	IL-!,	one	of	the	
elevated	mast	cell	mediators	in	SM	patients	(Zheng	et	al.,	#$%&).		
We	identified	a	subpopulation	in	the	CMP	that	expresses	FcεRI,	with	similar	expression	to	the	
circulating	MCP	 (Supplementary	 figure	 0	 in	 study	 III).	We	 therefore	 hypothesized	 that	 this	
subpopulation	harbored	mast	cell	potential.	In	vitro	cultures	showed	high	mast	cell	potential	
in	 the	 CMPFcεRI+,	 which	 we	 did	 not	 observe	 in	 CMPsFcεRI−	 and	 GMPs	 (Figure	 (	 and	
supplementary	 figure	 0	 in	 study	 III).	 Additional	 sorts	 of	 subpopulations	 of	 the	 CMPFcεRI+	
indicated	that	the	mast	cell	potential	different	comparing	CD*+,c+	and	CD'()c−	cells.	These	
findings	were	further	assessed	in	study	IV.	
As	 mentioned,	 the	 main	 aim	 of	 this	 study	 was	 to	 identify	 the	 KIT	 D"#$V	 mutation	 in	
hematopoiesis.	We	developed	a	highly	sensitive	method	to	detect	the	mutation	in	single	cells	
(Supplementary	figure	0	in	study	III).	We	found	that	the	majority	of	mast	cells	in	SM	patients	
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are	 mutated,	 with	 similar	 percentages	 in	 AdvSM	 compared	 to	 ISM	 (Figure	 (	 in	 study	 III).	
Interestingly	we	found	that	the	KIT	D"#$V	mutated	mast	cells	had	higher	CD&'RA	expression	
compared	 to	 mast	 cells	 that	 had	 normal	 KIT.	 As	 mentioned	 before,	 KIT	 D"#$V	 has	 been	
detected	 in	 multiple	 lineages,	 therefore	 we	 hypothesized	 that	 the	 mutation	 is	 present	 in	
multipotent	progenitors	and	that	it	is	enriched	in	the	mast	cell	lineage.	Indeed	we	found	the	
mutation	 throughout	 the	 hematopoietic	 landscape;	 however,	 we	 did	 not	 find	 a	 higher	
percentage	of	mutated	cells	in	the	CMPFcεRI+	population	(Figure	(F	in	study	III).	In	addition	we	
sorted	MCPs	from	blood	and	 found	a	similar	mutation	rate	 in	these	cells	compared	to	bone	
marrow	HSPCs	in	one	patient	(SM#$).	Thus,	the	high	mutation	rate	in	mature	mast	cells	was	
not	 reflected	 in	 any	 progenitor	 population.	 Instead,	 we	 found	 the	KIT	D"#$V	mutation	 in	
HSCs,	which	helps	our	understanding	about	the	onset	of	SM.		
It	 is	 estimated	 that	 about	 ()%	 of	 the	 SM	 patients	 carry	 KIT	 D"#$V	 (Valent	 et	 al.,	 +,-.).	
However,	 this	assumption	 is	based	on	mutation	analysis	of	DNA	 isolated	 from	whole	blood	
and	bone	marrow	or	 from	bulk-sorted	cells.	 It	was	reported	that	01/345	(07%)	ISM	patients	
carried	KIT	D"#$V	 in	 bulk	 sorted	 CD45+	 cells	 (Jara-Acevedo	 et	 al.,	 -./0).	With	 our	 highly	
sensitive	method	we	were	able	to	 find	only	a	 few	mutated	cells	 from	the	 in	total	more	than	
!"""	single	sorted	cells.	Using	DNA	from	sorted	CD56+	cells,	these	patients	would	likely	have	
been	identified	as	negative	for	KIT	D"#$V	in	progenitors.	Therefore	it	is	tempting	to	speculate	
that	 all	 SM	 patients	 carry	 the	KIT	D"#$V	mutation,	 but	 present	methodology	 is	 unable	 to	
detect	this,	however	 it	 is	currently	also	not	feasible	to	do	single	cell	DNA	analysis	on	all	SM	
patients.		
So	 when	 is	 the	 KIT	 D"#$V	 mutation	 first	 acquired?	 We	 know	 that	 it	 is	 not	 a	 germline	
mutation,	 so	 it	 is	 likely	 acquired	 spontaneously	 at	 a	 certain	 stage	 of	 development.	 One	
possibility	 is	 that	 there	 is	 one	 long-term	 HSC	 that	 acquires	 the	 KIT	 D"#$V	 mutation	 and	
produces	 daughter	 cells	 with	 the	 KIT	 D"#$V	mutation	 during	 a	 lifetime,	 resulting	 in	 an	
increased	 number	 of	 mutated	 mast	 cells	 with	 increased	 age.	 Another	 option	 is	 that	 the	
mutation	is	acquired	in	an	early	ancestor	cell	that	gives	hematopoietic	cells	and	mesenchymal	
cells.	 This	 theory	 is	 supported	 by	 the	 previously	 published	 data	 that	mesenchymal	 stromal	
cells	 express	 KIT	 D"#$V	 (Garcia-Montero	 et	 al.,	 ,-./;	 Nemeth	 et	 al.,	 ,-.4).	 However,	 it	
remains	 to	 be	 confirmed	 whether	 the	 mutation	 is	 acquired	 in	 a	 common	 ancestor	 or	
separately	 in	 hematopoietic	 and	 mesenchymal	 cell	 lineages.	 The	 existence	 of	 a	 common	
ancestor	 cell	 for	 hematopoietic	 and	 mesenchymal	 cells	 has	 not	 been	 shown	 so	 far,	 which	
makes	 it	unlikely	that	the	KIT	D"#$V	mutation	in	both	 lineages	arises	 from	the	same	clone.	
Also,	 as	 mentioned	 in	 the	 introduction	 of	 this	 thesis,	 hematopoietic	 stem	 cells	 arise	 from	
aorta-gonad-mesonephros	region	or	in	earlier	stages	from	the	extra-embryonic	yolk	sac.	If	this	
hypothetical	progenitor	of	HSCs	and	mesenchymal	 stem	cells	 exists,	 it	needs	 to	be	a	 cell	 at	
embryonic	development.	
KIT	is	expressed	in	progenitors,	but	not	required	for	MCP	survival,	as	we	showed	in	study	II.	In	
SM,	KIT	D"#$V	affects	mast	cells	shown	by	their	aberrant	phenotype	and	high	mutation	rate.	
In	contrast,	the	low	mutation	burden	in	MCPs	suggests	that	the	KIT	D"#$V	mutation	does	not	
affect	 differentiation	 of	 HSPCs	 and	 their	 function.	 Several	 studies	 reported	 multi-lineage	
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involvement	of	KIT	D"#$V,	as	we	confirmed	in	different	HSPCs,	but	so	far	there	are	no	studies	
showing	aberrant	function	of	other	cells	than	mast	cells	in	SM.	
Altogether,	this	study	provides	novel	insights	on	the	origin	of	the	KIT	D"#$V	mutation	in	stem	
and	progenitor	 cells	of	 SM	whereas	 the	overall	hematopoietic	profile	 is	unaffected.	We	also	
identified	CD*+RA	as	an	aberrant	marker	specific	for	SM	mast	cells,	which	can	be	used	as	an	
additional	 marker	 in	 diagnosis	 of	 patients.	 Furthermore,	 the	 observed	 enriched	 mast	 cell	
potential	in	the	FcεRI+	CMPs	provides	new	clues	on	mast	cell	origin	in	human	bone	marrow.	
4.4 MAST	CELL	AND	BASOPHIL	PROGENITORS	(STUDY	IV)	
The	bone	marrow	from	mice	contains	unipotent	and	bipotent	mast	cell	progenitors,	however,	
the	 existence	 of	 similar	 progenitors	 in	 the	 human	 bone	marrow	 is	 yet	 to	 be	 confirmed.	 In	
study	 III	 we	 described	 a	 bone	 marrow	 progenitor	 with	 mast	 cell	 potential	 that	 expressed	
FcεRI,	which	we	aimed	to	further	characterize	in	this	study.	
We	distinguished	subpopulations	within	the	CMPFcεRI+	population	using	the	markers	CD*+,c	
and	Integrin	β"	(Figure	(	in	study	IV).	In	vitro	cultures	showed	that	CD#$%c+	progenitors	only	
gave	 basophils	 and	 mast	 cells,	 whereas	 CD789c−	 progenitors	 exhibited	 the	 potential	 to	
differentiate	into	erythroid	cells,	as	well	as	basophils	and	mast	cells.	(Figure	(	and	,	in	study	
IV).		
The	lack	of	erythroid	potential	 in	CD456c+	CMPsFcεRI+	could	be	predicted	by	the	presence	of	
CD##	 surface	 expression,	 since	 this	marker	 is	known	 to	be	downregulated	during	 erythroid	
differentiation	(Figure	(	in	study	IV).	CD&&	is	a	marker	expressed	on	aberrant	mast	cells	in	a	
large	 cohort	 of	 patients,	 with	 the	 highest	 expression	 in	 ISM	 and	 well-differentiated	 SM	
(Dasilva-Freire	et	al.,	+,-.).	It	remains	to	be	investigated	whether	CD00	expression	is	affected	
in	the	mature	mast	cells	of	the	mastocytosis	patients	included	in	this	study.	
As	 mentioned	 in	 the	 introduction,	 several	 studies	 present	 data	 that	 argues	 for	 a	 shared	
differentiation	 trajectory	 for	 basophils,	 eosinophils,	 and	 mast	 cells.	 Culture	 experiments	
showed	 that	 eosinophils	develop	 from	an	 IL-!R+	 subpopulation	of	 the	CMP	 (Görgens	 et	 al.,	
!"#$;	Mori	et	al.,	!""1).	Mature	eosinophils	express	CD345c	and	Iβ",	like	basophils,	but	lack	
FcεRI.	Common	gating	strategies	use	a	combination	of	CD56	and	CD58	to	distinguish	between	
neutrophils	and	eosinophils,	CD23+	CD#$−	versus	CD)*+	CD#$+	respectively.	It	is	possible	that	
the	fraction	of	CD./+	expressing	cells	in	CMP	cultures	represents	eosinophils	(Figure	(	and	,	in	
study	 IV).	 However,	 in	 vitro	 cultures	 of	 human	 pluripotent	 stem	 cells	 in	 medium	
supplemented	with	IL-!	and	IL-!	showed	that	eosinophils	did	not	express	CD3!	after	5-!	days	
(Choi	 et	 al.,	 !"##).	 In	 addition,	 the	 CD/0+	 population	 from	 cultured	 CMPsFcεRI−	 was	
phenotypically	similar	to	the	CD23+	cells	from	cultured	GMPs,	which	makes	it	more	likely	that	
they	represent	a	pre-monocyte-neutrophil	cell.		
Our	 culture	 system	 did	 not	 assess	 the	 megakaryocyte	 potential.	 As	 mentioned	 in	 the	
introduction	of	 this	 thesis,	 classical	hematopoiesis	models	describe	 a	 shared	megakaryocyte	
and	erythroid	progenitor	that	arises	from	the	CMP	and	MEP.	More	recent	studies	suggest	that	
megakaryocytes	can	develop	directly	from	the	HSC.	Since	some	CMPsFcεRI+	progenitors	in	our	
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model	still	have	erythroid	potential,	it	will	be	interesting	to	assess	whether	these	cells	have	any	
megakaryocyte	 potential.	 The	 difficulty	 with	 analyzing	 cell-potential	 with	 culture	medium	
that	stimulates	all	 lineages	 is	 that	hematopoietic	cells	differentiate	 in	different	growth	rates;	
for	 example,	 about	 //%	 of	 all	 the	 blood	 cellular	 components	 consist	 of	 erythrocytes	 and	
platelets.	 Thus,	 whereas	 a	 culture	 systems	 with	 only	 limited	 growth	 factors	 might	 give	 a	
limited	 differentiation	 and	 create	 biased	 data,	 addition	 of	multi-lineage	 stimulating	 growth	
factors	 results	 in	 a	 more	 realistic	 differentiation	 with	 mainly	 erythrocytes	 and	 platelets,	 in	
which	 rare	 populations	 are	 difficult	 to	 detect.	 Therefore,	 in	 this	 study	 we	 cultured	 cells	 in	
limited	medium	conditions	to	identify	the	basophil-mast	cell	potential	as	well	as	multilineage	
medium	conditions	to	assess	the	potency	to	form	other	cells.	
In	this	study	we	measured	cell-potential	by	flow	cytometry	analysis,	whereas	there	are	other	
methods	 to	 define	 the	 cell	 composition,	 such	 as	 immunohistochemistry	 or	 RNA-expression	
analysis.	Flow	cytometry	analysis	was	our	preferred	method	since	it	enabled	us	to	assess	the	
expression	of	multiple	cell	surface	receptors	in	one	panel	of	limited	cell	numbers,	including	a	
live-dead	marker	to	only	compare	expression	in	living	cells.	We	included	other	markers	in	the	
panel,	such	as	CD./0	(IL-!R),	siglec-!,	and	CD))b,	however	these	marker	were	not	expressed	
or	 did	 not	 give	 sufficient	 staining	 to	 draw	 conclusions	 on	 their	 expression.	 In	 future	
experiment	 it	 would	 be	 interesting	 to	 include	 other	 markers,	 such	 as	 CXCR$,	 to	 identify	
basophils	and	eosinophils,	and	confirm	the	identity	of	cultured	cells	by	morphology	staining	
and	RNA-expression	analysis.	
Taken	together,	this	study	provides	novel	insights	in	the	cell-forming	potential	of	a	subset	of	
CMPs.	 We	 show	 a	 clear	 separation	 in	 differentiation	 of	 myeloid	 cells	 in	 our	 culture	
experiments.	It	is	interesting	to	speculate	why	mast	cells,	basophils	and	likely	eosinophils	are	
closely	related	to	the	erythroid	and	megakaryocyte	lineage,	especially	since	their	morphology	
and	function	is	more	similar	to	other	granulocytes.		
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5 CONCLUDING	REMARKS	AND	OUTLOOK	
We	 aimed	 to	 gain	more	 insight	 in	 a	 rare	 cell	 type	 and	 a	 rare	 disease,	 creating	 challenging	
projects.	The	expertise	 in	our	 lab	and	available	methods,	together	with	a	great	collaboration	
with	 clinicians,	 made	 it	 possible	 to	 study	 mast	 cell	 development.	However,	 there	 are	 still	
several	open	questions	on	basic	mast	cell	development	and	the	role	of	mast	cells	in	systemic	
mastocytosis,	providing	a	starting	point	for	further	research.	
Combining	 the	 data	 in	 these	 studies,	we	 revealed	 new	 concepts	 on	mast	 cell	development:	
their	close	relation	to	the	erythroid	trajectory	and	not	to	neutrophils,	as	well	as	the	role	of	SCF	
and	KIT-signaling	in	initial	mast	cell	differentiation.	Given	that	KIT-signaling	is	not	required,	
what	 factors	 drive	 mast	 cell	 differentiation?	 Signaling	 through	 the	 IL-!R	 resulted	 in	 MCP	
survival	 and	 proliferation,	whereas	 IL-!	 is	mainly	 known	 for	 basophil	maturation,	 so	which	
other	factors	drive	mast	cells	differentiation,	or	is	basophil	and	mast	cell	development	shared	
until	they	leave	the	bone	marrow	as	MCP	or	basophil?	And	if	we	go	a	step	back	in	hierarchy,	
what	separates	mast	cell,	basophil,	and	eosinophil	from	neutrophil	development?		
The	finding	that	KIT-signaling	is	not	required	in	early	mast	cell	development	explains	why	the	
KIT	 D"#$V	 mutation	 does	 not	 affect	 the	 hematopoiesis	 landscape	 in	 SM	 patients.	 As	 a	
consequence,	the	effects	of	this	mutation	is	only	noticed	when	mast	cells	mature	and	require	
KIT-signaling	 for	 their	 normal	 function.	Recently	 a	 leukemic	 initiating	 cell	 population	 was	
reported	in	MCL	and	it	would	be	interesting	to	assess	whether	these	cells	express	KIT	D"#$V	
and	if	this	is	involved	in	the	development	of	mastocytosis.		
Currently	there	is	still	limited	knowledge	on	the	role	of	KIT	D"#$V	in	disease	ontology;	what	
causes	 the	KIT	D"#$V	mutation	 and	 is	 this	 mutation	 the	 driver	 in	 SM?	 If	 it	 is	 not	 in	 the	
germline,	where	does	it	first	arise?	Does	is	arise	spontaneously?	On	the	other	hand,	the	D%&'V	
mutation	is	not	the	only	mutation	found	in	the	KIT	receptor,	as	there	have	been	more	than	
!""	 reported	 KIT	 mutations.	 So,	 what	 makes	 this	 receptor	 so	 vulnerable	 to	 genetic	
alterations?	In	this	thesis	we	studied	the	KIT	D"#$V	in	relation	to	the	mast	cell	 lineage,	but	
what	 is	 the	effect	of	KIT	D"#$V	on	the	development	of	other	cell	 lineages?	And	what	 is	 the	
prevalence	 and	 role	 of	 other	 associated	mutations	 in	 these	KIT	D"#$V	mutated	 cells?	The	
development	of	high-throughput	single	cell	genome	sequencing	techniques	will	be	very	useful	
for	answering	these	questions,	but	these	techniques	are	still	in	the	developmental	stage.	It	will	
be	 very	 interesting	 to	 create	 a	 genetic	 footprint	 of	 the	 patients	 that	 allows	 for	 better	 and	
personalized	treatment,	as	is	currently	seen	for	other	myeloid	neoplasms.	
Besides	the	presence	of	KIT	D"#$V	throughout	the	hematopoietic	landscape,	we	present	other	
novel	findings	on	SM	ontology:	SM-specific	CD#$RA	expressing	mast	cells	and	the	presence	of	
circulating	mast	cells	in	advanced	SM.	These	findings	are	relevant	for	basic	understanding	of	
SM,	but	can	also	be	applied	in	the	clinic.	However,	implementation	of	findings	in	translational	
research	is	challenging.	For	example,	in	order	to	be	implemented	as	diagnostic	criterion	or	in	
prognostic	research,	our	findings	need	to	be	confirmed	in	a	larger	cohort	of	patients.	This	may	
prove	 to	 be	 more	 difficult	 than	 expected,	 as	 this	 is	 usually	 not	 of	 interest	 of	 fundamental	
scientists,	and	clinicians	might	not	see	the	importance	of	this	either.	Thus,	a	challenge	for	the	
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future	 is	 to	 further	 improve	 collaborations	 between	 scientists	and	 clinicians	 especially	 for	 a	
rare	disease	 like	SM.	A	good	example	 in	which	this	 is	pursued	 is	 the	European	Competence	
Network	on	Mastocytosis,	a	network	with	 fundamental	scientists	and	clinicians.	Within	this	
network,	clinicians	and	scientists	share	knowledge	on	SM	and	aim	for	improved	recognition,	
diagnosis,	and	therapy.	In	addition,	most	countries	within	Europe	have	a	center	of	excellence	
or	 a	 reference	 center	 consisting	 of	 local	 scientist	 and	 clinicians	 who	 focus	 on	 SM	 and	 can	
provide	advice	to	hospitals	or	universities.	
In	conclusion,	the	research	conducted	in	this	thesis	provides	novel	insights	and	on	mast	cell	
development	 in	 health	 and	 systemic	 mastocytosis,	 which	 in	 the	 end	 will	 hopefully	 be	
beneficial	for	the	patients	suffering	from	mast	cell	activation	diseases.	
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6 POPULAR	SCIENCE	SUMMARY	
All	 white	 blood	 cells	 origin	 from	 a	 stem	 cell,	 called	 the	 hematopoietic	 stem	 cell.	 This	
hematopoietic	 stem	 cell	 is	 located	 in	 the	 bone	marrow	 and	 forms	 supplies	 your	 body	with	
blood	cells,	 including	white	blood	cells,	red	blood	cells	and	platelets,	during	your	whole	life.	
Mast	 cells	 are	 a	 type	 of	 white	 blood	 cell,	 which	 detect	 stranger	 of	 danger	 signals	 that	 are	
potentially	harmful.	Some	white	blood	cells	circulate	in	the	blood,	others,	like	the	mast	cell	are	
living	in	tissues	or	organs.		
When	 a	 stem	 cell	 develops	 into	 a	 mature	 white	 blood	 cell,	 it	 starts	 to	 change	 the	 DNA	
expression	inside	the	cell,	which	in	turn	results	into	changes	in	the	receptors	(signal	receivers)	
on	the	surface	of	the	cell.	Before	a	stem	cell	transforms	into	a	mast	cell,	it	first	becomes	a	mast	
cell	precursor	that	leaves	the	bone	marrow	and	enters	the	blood	stream.	When	this	mast	cell	
precursor	 arrives	 at	 its	destination,	 it	moves	 into	 the	 tissue	 and	matures.	 There	 are	 several	
different	methods	available	nowadays	 to	detect	 these	changes	on	 the	surface	and	 inside	 the	
cell.	We	can	identify	mast	cells	from	other	white	blood	cells	by	their	specific	receptors	on	the	
surface,	and	by	the	DNA	expression	in	the	cell.	For	example,	mature	mast	cells	have	a	lot	of	
the	receptors	called	KIT	and	FcεRI.	We	can	label	these	receptors	with	a	fluorescent	label	and	
detect	them	using	a	flow	cytometer.	In	total	we	can	detect	up	to	34	different	receptors	on	one	
cell,	making	 it	 possible	 to	detect	 all	 different	 kinds	of	white	blood	 cells	 in	 a	blood	or	bone	
marrow	 sample.	Using	 this	method	we	 can	 also	 identify	 new	 cells,	 or	 new	 receptors	on	 an	
already	known	cell.	This	method	is	well	established	in	this	research	field	and	therefore	used	in	
all	four	studies	that	are	the	basis	of	this	thesis.	
The	overall	aim	of	this	thesis	project	was	to	get	a	better	understanding	on	normal	mast	cell	
development	 and	 mast	 cell	 development	 in	 a	 disease	 called	 systemic	 mastocytosis.	 In	 this	
disease,	 most	 of	 the	 mast	 cells	 have	 a	 mutation	 in	 the	 receptor	 KIT	 called	 D+,!V.	 This	
mutation	affects	the	function	of	mast	cells,	which	in	most	cases	results	in	an	increase	of	these	
mast	cells	in	the	skin	(presented	as	typical	brown-red	spots)	or	in	the	bone	marrow,	the	liver,	
the	spleen,	or	the	intestine.	Patients	that	have	a	mild	form	of	the	disease	have	symptoms	such	
as	hives,	itching,	and	gastrointestinal	problems.	When	the	disease	is	aggressive,	the	mast	cells	
start	damaging	the	tissues	or	organs	that	 they	 infiltrated.	Patients	 living	with	the	mild	 form	
have	 a	 normal	 life	 expectancy,	 whereas	 patients	 with	 the	 aggressive	 disease	 have	 a	 bad	
prognosis	of	only	a	few	months	to	years.	At	the	moment	there	is	no	cure	and	patients	mainly	
take	symptom-reducing	medication.	
This	thesis	contains	four	studies	that	will	help	to	answer	the	aim	of	the	thesis:	
In	study	I	we	analyzed	blood	samples	from	patients	with	different	forms	of	mastocytosis.	We	
found	 that	 patients	 with	 the	 aggressive	 form	 of	 the	 disease	 have	 mature	mast	 cells	 in	 the	
blood,	which	are	absent	in	the	mild	form	and	healthy	persons.	
In	study	II	we	investigated	what	signals	are	necessary	for	the	development	of	mast	cells.	We	
found	that	the	receptor	KIT	is	important	for	the	mast	cell	to	get	fully	mature,	but	not	for	the	
initial	development	from	the	stem	cell.	
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In	study	III	we	developed	a	method	that	detects	the	D&'(V	mutation	on	the	receptor	KIT	in	
single	 cells	 from	patients	 to	 identify	where	 this	mutation	 comes	 from.	We	could	detect	 the	
mutation	in	a	small	percentage	of	the	stem	cells	from	the	patients.	In	contrast,	almost	all	mast	
cells	 in	 the	same	patient	have	 the	mutation.	Further	analysis	of	 the	bone	marrow	cells	with	
flow	cytometry	showed	that	the	mast	cells	in	the	patients	have	an	abnormal	receptor	on	their	
cell	 surface,	 called	 CD()RA.	 In	 addition,	 we	 found	 a	 rare	 cell	 in	 the	 bone	 marrow	 that	
developed	into	mast	cells	when	we	isolated	this	cell	and	cultured	it	in	the	lab.		
In	study	IV	we	continued	to	analyze	the	rare	mast	cell	precursors	that	we	identified	in	study	
III.	 By	 isolating	 developing	 cells	 and	 culturing	 them	 in	 the	 lab,	 we	 found	 that	 mast	 cells	
development	is	closely	related	to	the	development	of	another	white	blood	cell,	the	basophil.	
To	sum	up,	the	data	in	the	studies	of	this	thesis	help	us	to	get	a	better	basic	understanding	of	
mast	 cell	 development	 in	 healthy	 persons	 and	 in	 patients	 with	 systemic	mastocytosis.	 The	
findings	 in	all	 four	studies	are	useful	 for	the	field	of	basic	mast	cell	research	and	for	clinical	
research	in	which	we	aim	to	identify	new	targets	to	treat	mastocytosis	patients.		
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7 POPULAIR	WETENSCHAPPELIJKE	SAMENVATTING	
Alle	witte	bloedcellen	komen	van	een	 stamcel	die	we	de	hematopoëtische	 stamcel	noemen.	
Deze	 hematopoëtische	 stamcel	 bevindt	 zich	 in	 het	 beenmerg	 en	 vormt	 gedurende	 je	 hele	
leven	 alle	 soorten	 bloedcellen,	 zoals	 witte	 bloedcellen,	 rode	 bloedcellen	 en	 bloedplaatjes.	
Mestcellen	 zijn	 een	 soort	 witte	 bloedcel	 die	 in	 je	 lichaam	 vreemde	 en	 gevaarlijke	 signalen	
kunnen	herkennen	die	potentieel	schadelijk	voor	je	zijn.	Sommige	witte	bloedcellen	circuleren	
in	het	bloed,	anderen,	zoals	de	mestcel,	leven	in	weefsels	of	in	organen.	
Als	een	stamcel	zich	tot	een	mestcel	ontwikkelt	verandert	de	expressie	van	het	DNA	in	de	cel	
en	de	 expressie	 van	 receptoren	 (signaalontvangers)	die	op	de	 buitenkant	 van	 de	 cel	 zitten.	
Voordat	een	stamcel	zich	tot	een	volwassen	mestcel	ontwikkelt,	verlaat	de	cel	het	beenmerg	
als	voorloper	mestcel	en	gaat	het	de	bloedstroom	in.	Zodra	de	voorloper	mestcel	aankomt	op	
zijn	 bestemming,	 verlaat	 deze	 het	 bloed,	 migreert	 naar	 het	 weefsel,	 en	 rijpt	 verder	 tot	
volwassen	 mestcel.	 Er	 zijn	 tegenwoordig	 verschillende	 methoden	 beschikbaar	 om	 deze	
veranderingen	in	de	cel	en	op	de	buitenkant	van	de	cel	te	meten.	Zo	kunnen	we	mestcellen	
van	andere	witte	bloedcellen	onderscheiden	door	hun	specifieke	DNA	expressie	en	specifieke	
receptoren.	Volwassen	mestcellen	hebben	bijvoorbeeld	veel	van	de	receptoren	KIT	en	FcεRI.	
We	kunnen	deze	receptoren	labelen	met	een	fluorescerend	label	en	dat	vervolgens	meten	met	
een	flow	cytometer.	Met	deze	methode	kunnen	we	in	totaal	67	verschillende	receptoren	meten	
op	een	enkele	cel,	wat	het	mogelijk	maakt	om	verschillende	witte	bloedcellen	in	het	bloed	en	
in	het	beenmerg	te	identificeren.	Met	deze	methode	kunnen	we	ook	nieuwe	cellen	of	nieuwe	
receptoren	 identificeren.	 Deze	 methode	 is	 ver	 ontwikkeld	 in	 dit	 onderzoeksgebied	 en	 is	
daarom	ook	de	basis	voor	alle	vier	de	studies	in	dit	proefschrift.	
Het	doel	van	dit	proefschrift	is	om	een	beter	beeld	te	krijgen	van	de	normale	ontwikkeling	van	
de	 mestcel	 in	 vergelijking	 met	 de	 ontwikkeling	 van	 de	 mestcel	 in	 de	 ziekte	 systematische	
mastocytose.	 Deze	 ziekte	 wordt	 gekenmerkt	 door	 de	 aanwezigheid	 van	 een	 mutatie	 in	 de	
receptor	 KIT,	 genaamd	 D234V.	 De	 mutatie	 heeft	 invloed	 op	 de	 functie	 van	 mestcellen	
waardoor	deze	mestcellen	toenemen	in	de	huid	(waargenomen	als	typische	bruinrode	vlekjes)	
of	 in	 het	 beenmerg,	 de	 lever,	 de	 milt	 of	 de	 darmen.	 Patiënten	 met	 een	 milde	 vorm	 van	
mastocytose	hebben	symptomen	zoals	opvliegers,	jeuk	of	darmproblemen.	Wanneer	er	sprake	
is	 van	 een	 agressieve	 vorm,	 kunnen	 de	 mestcellen	 schade	 toebrengen	 aan	 de	 weefsels	 en	
organen	 die	 ze	 hebben	 geïnfiltreerd.	 Patiënten	 met	 een	 milde	 vorm	 hebben	 een	 normale	
levensverwachting,	maar	patiënten	met	een	agressieve	vorm	hebben	een	slechte	prognose	van	
een	paar	maanden	tot	jaren.	Op	dit	moment	is	mastocytose	niet	te	genezen	en	behandelingen	
zijn	daardoor	gericht	op	het	bestrijden	van	de	symptomen.	
Dit	proefschrift	is	gebaseerd	op	vier	studies:	
In	studie	I	bestudeerden	we	bloed	van	patiënten	met	verschillende	vormen	van	mastocytose.	
De	resultaten	toonden	aan	dat	patiënten	met	een	agressieve	vorm	van	mastocytose	volwassen	
mestcellen	hebben	in	het	bloed,	maar	dat	deze	afwezig	zijn	in	patiënten	met	een	milde	vorm	
en	in	gezonde	personen.	
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In	 studie	 II	 onderzochten	 we	 welke	 signalen	 belangrijk	 zijn	 voor	 de	 ontwikkeling	 van	
mestcellen.	Celkweek	experimenten	lieten	zien	dat	de	receptor	KIT	niet	belangrijk	is	voor	de	
initiële	ontwikkeling	van	de	stamcel	tot	mestcel,	maar	wel	voor	de	uiteindelijke	rijping	van	de	
mestcel.	
In	studie	III	ontwikkelden	we	een	methode	om	de	mutatie	D./0V	in	de	receptor	KIT	in	een	
enkele	 cel	 te	 kunnen	 detecteren	 om	 vervolgens	 de	 oorsprong	 van	 deze	 mutatie	 in	
voorlopercellen	vast	te	stellen.	De	mutatie	was	aanwezig	in	een	deel	van	de	stamcellen	van	de	
patiënten	en	in	bijna	alle	volwassen	mestcellen	van	dezelfde	patiënt.	Door	verdere	analyse	van	
het	 beenmerg	 met	 de	 flow	 cytometer	 ontdekten	 we	 een	 nieuw	 signaalmolecuul	 dat	 alleen	
aanwezig	 is	 op	 mestcellen	 van	 patiënten,	 genaamd	 CD67RA.	 Verder	 hebben	 we	 ook	 een	
zeldzame	voorlopercel	in	het	beenmerg	gevonden	die	zich	in	kweek	tot	mestcel	ontwikkelt.	
In	 studie	 IV	 gingen	 we	 verder	 met	 het	 analyseren	 van	 de	 zeldzame	 voorlopercel	 in	 het	
beenmerg	die	we	in	studie	III	hadden	gevonden.	Door	deze	voorlopercellen	te	isoleren	en	in	
het	lab	te	kweken	vonden	we	dat	de	ontwikkeling	van	mestcellen	nauw	is	verbonden	met	de	
ontwikkeling	van	een	andere	witte	bloedcel,	de	basofiel.	
Samengevat,	de	resultaten	in	dit	proefschrift	zijn	belangrijk	om	een	beter	beeld	te	krijgen	over	
de	 ontwikkeling	 van	 mestcellen	 in	 gezonde	 personen	 en	 patiënten	 met	 mastocytose.	 De	
bevindingen	hebben	toegevoegde	waarde	 in	 fundamenteel	onderzoek	naar	mestcellen,	maar	
ook	 voor	 klinisch	 onderzoek	 dat	 gericht	 is	 op	 het	 ontwikkelen	 van	 een	 betere	behandeling	
voor	mastocytose	patiënten.	
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